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THE DIAMOND HEMESEP BLOOD PROCESSING UNIT: A
REAL-TIME MICROFLUIDIC WHOLE BLOOD SEPARATION
PROCESS
Abstract
Recent advancements in the field of microfabrication and microfluidics have made possible the design of
separation devices and clinical diagnostic kits that use relatively smaller volumes of sample material than
existing technologies. Using this technology, as well as existing technologies in membrane and
immunomagnetic separations, a novel blood processing unit based on microfluidics has been designed. This
report will detail the operation and layout of a microfluidic chip that produces three outputs (serum, plasma
and a white blood cell lysate) from a human whole blood input. Microfluidic technology has allowed for the
design of several distinctive features that make the performance of the blood processing unit comparable to
existing centrifuge technologies available clinically and in research laboratories. Among other features, the
chip produces a stabilized white blood cell lysate and is designed to match the blueprint of existing 96-well
plates. In addition to describing the on-board processes and features of the chip, this report will also discuss
the components needed for operation of the chip as well as a process to manufacture the product.
This product, known as the Diamond HemeSep blood processing unit, could offer more standardized,
efficient blood separation technologies that would benefit health care providers, patients and researchers.
Moreover, the product is predicted to have a healthy financial outlook: based on the target market of clinical
laboratories performing preclinical and clinical trials involving numerous samples of blood, we expect to sell 1
million cartridges in the first year of production with sales growing to 1.7 million cartridges in the tenth and
final year. The net present value (NPV) of the proposed project, based on a selling price of $25 a cartridge, is
expected to be $51 million. For the current projections, Series A investors can expect returns of 45%.
This working paper is available at ScholarlyCommons: http://repository.upenn.edu/cbe_sdr/35
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Chapter 1: Abstract 
 
 Recent advancements in the field of microfabrication and microfluidics have made 
possible the design of separation devices and clinical diagnostic kits that use relatively smaller 
volumes of sample material than existing technologies.  Using this technology, as well as 
existing technologies in membrane and immunomagnetic separations, a novel blood processing 
unit based on microfluidics has been designed.  This report will detail the operation and layout of 
a microfluidic chip that produces three outputs (serum, plasma and a white blood cell lysate) 
from a human whole blood input. Microfluidic technology has allowed for the design of several 
distinctive features that make the performance of the blood processing unit comparable to 
existing centrifuge technologies available clinically and in research laboratories.  Among other 
features, the chip produces a stabilized white blood cell lysate and is designed to match the 
blueprint of existing 96-well plates.  In addition to describing the on-board processes and 
features of the chip, this report will also discuss the components needed for operation of the chip 
as well as a process to manufacture the product. 
 This product, known as the Diamond HemeSep blood processing unit, could offer more 
standardized, efficient blood separation technologies that would benefit health care providers, 
patients and researchers.  Moreover, the product is predicted to have a healthy financial outlook: 
based on the target market of clinical laboratories performing preclinical and clinical trials 
involving numerous samples of blood, we expect to sell 1 million cartridges in the first year of 
production with sales growing to 1.7 million cartridges in the tenth and final year.  The net 
present value (NPV) of the proposed project, based on a selling price of $25 a cartridge, is 
expected to be $51 million.  For the current projections, Series A investors can expect returns of 
45%. 
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Chapter 2: Introduction 
2.1 Introduction 
 
 Human whole blood is a complex bodily fluid that delivers oxygen and nutrients to the 
body’s other organs and tissues.  Whole blood is composed of red and white blood cells 
suspended in liquid called plasma (as described in detail in Chapter 5).  Ordinarily, blood is 
separated into fractions of red blood cells, white blood cells and plasma through centrifugation, 
which takes advantage of the difference in buoyant densities of these different fractions.  Plasma 
is then further purified into serum by chemically precipitating out the clotting factors.  These 
various blood fractions are useful for analysis in many clinical and research settings.  Knowledge 
about an individual’s ion levels, coagulation system and a full DNA profile from white blood cell 
lysate can be useful for appropriate treatment and research during and following surgery, 
infection, or for other forms of diagnostics and therapies. 
 The Diamond HemeSep cartridge, as described in this report, presents an innovative 
design for blood processing and separation.  Our cartridge uses advancements in microfluidics, 
immunomagnetic separation and filtration to provide a stabilized white blood cell lysate, a 
plasma fraction and a serum fraction as outputs in a small, self-contained package.  With the 
aforementioned features, the cartridge’s performance should be comparable to traditional blood 
processing technologies such as centrifugation. 
 Traditional blood processing has been performed using centrifugation (as described in 
Chapter 3).  However, this procedure introduces unnecessary and inconvenient variability 
between samples dependent on the human operator conducting the analysis at the time.  
Furthermore, this procedure requires relatively large sample volumes and can be time 
consuming.  Especially in analyses following a surgery or trauma, more immediate results are 
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often desired.  In developing the Diamond HemeSep cartridge, we have addressed these concerns 
by standardizing the separation process and removing the need for consistent human presence 
during the separation procedure while maintaining the reliability and stability of existing 
technologies. 
 The Diamond HemeSep blood processing unit will initially be marketed for use in 
clinical research facilities that require blood to be processed for subsequent analysis.  In such a 
clinical setting, the product may improve reproducibility of results and reduce waiting times in 
the labs, ultimately allowing for better patient care and scientific progress.  It will do so by 
allowing physicians and researchers to acquire information that may be useful from their blood 
samples in a more timely fashion. 
 Chapter 5 describes the basic biology of human whole blood and briefly discusses the 
relevant chemistry of blood coagulation for the purpose of serum filtration from blood plasma, 
respectively.  This chapter also discusses technologies currently in existence to fractionate blood 
and prevent and produce clotting.  The Diamond HemeSep cartridge will produce the same blood 
fractions that current centrifugation technology can produce as well as further processing the 
white blood cell fraction to a DNA stabilized cell lysate.  A novel benefit of the cartridge is the 
ability to produce and process all fractions of blood from a small starting sample volume 
simultaneously at the end of the processing time.  This means that less blood needs to be 
collected from the patient and physicians and researchers do not have to wait for the samples to 
be processed in a laboratory by a human technician.   
 Chapter 6 introduces the scientific background information on the microfluidic design 
presented in Chapter 4 for separating plasma from the other blood components.  While this 
method is not commonly in use, it is capable of producing nearly pure plasma fractions using 
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microliter scale samples of blood.  The method works based on the Zweifach-Fung effect, which  
predicts that blood, when flowing through a main channel into a bifurcation, will fractionate into 
a cell fraction and plasma fraction based on the ratio of flow in the two daughter channels.  For 
reasons described in Chapter 6, the blood cells will tend to flow into the larger channel with the 
lower flow rate.  Chapter 9 discusses the manufacture of the microfluidic channels using a 
technique known as soft lithography. 
 Chapter 7 introduces the use of an antibody based system for white blood cell isolation 
from whole blood.  The technique is based upon the affinity of antibodies, proteins produced by 
the immune system, for their ligands (in this case, white blood cells).  After binding to their 
substrate, the antibodies, which are connected to a paramagnetic bead, can be concentrated to the 
bottom of a well along with the bound white blood cells to facilitate separation.  The selection of 
an antibody and a more detailed explanation of the technique are presented. 
 Filtration as a mechanism for separating blood serum from plasma is discussed in 
Chapter 8.  In addition, this chapter discusses the basic chemical reactions involved in 
coagulating and clotting blood so that the clots may be removed from plasma to produce a serum 
fraction. 
 In chapter 4, we present the layout of the microfluidic portion of the Diamond HemeSep 
cartridge, the design of the immunomagnetic separation for white blood cell and the specifics of 
the filtration system for filtering plasma into serum.  These details include the geometry and 
spatial location of the various components and separation units on the cartridge as well as 
process flow diagrams that detail scheduling for the liquid handling unit. 
 A process for the manufacture of the Diamond HemeSep cartridge is outlined in Chapter 
10.  The microfluidic chips will be designed and prototyped internally, but mass produced 
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through an external vendor.  However, the chips must be assembled onto the cartridge along with 
the tips and reagents needed for the other separation processes prior to packaging and shipping.  
Integral to proper performance of the cartridge is ensuring that the appropriate microliter 
volumes of sample and reagent can be delivered to their proper locations.  To accomplish this, a 
liquid handling system will be used.  While other engineering specialties, such as mechanical 
engineering, will need to be consulted to further develop this processing/handling tower, we have 
provided estimates for size and cost of the equipment needed.  The manufacture of this tower as 
discussed in Chapter 10 will be outsourced to an experienced liquid handling company with 
revenues coming from both cartridge and unit sales. 
 After outlining these design considerations, Chapter 11 briefly elaborates on a proposed 
development timeline for the product.  Integral to the success of any such medical device is 
acquiring FDA approval.  The financial analyses presented in Chapter 12 will discuss the 
sensitivity of product success on delays in FDA approval. 
 Finally, the financial analysis examines numerous other scenarios, including the effects 
of varying product price and market penetration.  Using an assumed selling price of $25 per one 
time use cartridge, the NPV of the product is calculated to be roughly $51 M.  With further 
market research, product sales could grow beyond the assumed values presented herein. 
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2.2 Project Charter and Scope 
 
Project Name Microfluidic Blood Processing Unit 
Project Champions Scott Diamond, PhD 
Project Leaders Dan Moonan, Chinmay Paranjape, Jack Tirone, Kristina Wang  
Specific Goals Develop a microfluidic blood processing unit that can separate a 5mL 
sample of whole blood into plasma, serum, and white blood cells in 20 
minutes.  
Project Scope In-scope: 
-Basic design of the disposable microfluidic cartridge 
-Define separation processes 
-Manufacturing procedure 
-Economic analysis 
-Experiment with designs of microfluidic chip 
 
Deliverables Business opportunity 
Market expansion 
Technical feasibility 
Manufacturing capability assessment 
Competitive product analysis 
Laboratory data analysis 
Timeline -The project feasibility and design stages will take place over the course 
of approximately 3 months 
2.3 Purpose of Processing Blood  
 
Preclinical and clinical trials often involve the collection and processing of blood to obtain 
erythrocyte, leukocyte, and platelet cell counts, as well as stable serum and plasma samples. Techniques 
such as proteomics, metabolomics, and DNA analysis often involve assays and require efficient isolation 
of specific blood components. Plasma and serum are harvested and stored for analysis of analytes, 
biomarkers, etc. As well, the leukocyte samples are often used for later preparation of DNA or for 
constructing DNA archives (1). 
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2.4 Innovation Map 
 
 An innovation map is used to address the need for new technologies when preparing a new 
product. As discussed by Seider et al., an innovation map has six levels. Listing these levels from top to 
bottom, they are: customer-value proposition, products, product technology, technical differentiation, 
process/manufacturing technology, and materials technology. The map connects these levels by stating 
which new technological features will be used in the development of the product (1, 2). 
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Chapter 3: Market Analysis 
3.1 Markets for the Diamond HemeSep 
 
  As directed in the design statement, the Diamond HemeSep will initially be marketed toward use 
in pre-clinical and clinical trials. The Diamond HemeSep will offer significant value to the research 
community by eliminating inefficiencies in current practices of processing blood. Our initial target 
customers are pharmaceutical companies, biotechnology research and development companies, and 
hospital and clinical laboratories. The size of this market has been estimated based on the number of 
clinical sites and blood samples. As outlined in the design statement, we assume a market space of 1000 
clinical sites that process 1 million blood samples a year in the U.S.  
 We have also identified other potential applications of the Diamond HemeSep. During product 
prototyping, entrance into the other blood markets described below should be considered to explore the 
possibility of significantly increasing revenue.  
Aside from research purposes, quantification of components in blood, such as leukocytes, 
platelets, and serum proteins, is routine for the diagnosis and monitoring of many diseases. For example, 
quantification of serum proteins is used as a diagnostic test for diseases such as paraproteinaemias, 
hemoglobinopathies, and genetic abnormalities (2).  The Diamond HemeSep may allow physicians and 
scientists to exercise point-of-care diagnosis and acquire information in a timely manner. Furthermore, in 
many surgeries, especially cardiac surgeries undergoing cardiac pulmonary bypass (CPB), there is an 
unmet medical need to monitor inflammation by fractionating blood and measuring the concentration of 
clinically relevant proteins (1-3). Exposure of blood to non-physiological surfaces of the cardiopulmonary 
bypass, hypothermia, surgical trauma, and ischemia-reperfusion of the involved tissues induces complex 
inflammatory responses and are considered as main factors causing postoperative complications. These 
complications include vital organ dysfunction that can lead to multi-organ failure and even death. The 
intensity of the inflammatory response appears to be directly correlated with the severity of CPB-related 
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morbidity. Currently, there is no effective method for preventing this systemic inflammatory response 
syndrome in cardiac surgery patients undergoing CPB. Therefore, the Diamond HemeSep can potentially 
fulfill this unmet medical need by offering a safe and effective therapeutic diagnostic to monitor the 
inflammatory response in surgeries.    
Thus, in addition to the research market, the Diamond HemeSep may be applicable to various 
diagnostic markets. Our other potential targeted customers include physicians’ offices, nursing homes, 
and surgery operating rooms, where access to a clinical laboratory is limited.  
3.2 Customer Requirements 
 
 Considering the needs and features required by potential customers is crucial to designing a new 
product and will most likely determine whether the product succeeds or fails. Customer requirements are 
determined by analyzing data from the market survey and researching competing products. Once a list of 
customer requirements is compiled, each requirement is given a weighting factor to designate its degree 
of importance and is also classified as either fitness-to-standard (FTS) or new-unique-difficult (NUD). 
Table 3.1 shows the desired customer requirements (2).  
Customer Requirement Product Requirements Type Weighting 
Factor (%) 
Pure blood fractions 
 
Instrument/measurement quality 
 
FTS 20 
Reproducible blood fractions 
Instrument/measurement quality 
 
NUD 20 
Minimization of labor 
involvement 
Automation  NUD 15 
Faster processing time Automation  NUD 15 
Low whole blood input 
volume 
Low whole blood input volume FTS 5 
Portability Instruments that occupy least space FTS 10 
Low cost Cost-effective separation method FTS 15 
Table 3.1: Customer requirements 
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3.2.1 Critical-to-Quality variables 
 
 The customer requirements from the previous section must be translated into technical 
requirements that can be manufactured and used in the design of the device. These technical requirements 
are also called critical-to-quality variables (CTQ) and relate to specific target values. The target values 
have been determined by researching competing products and industry standards (2, 6).  
Product Requirement Technical Requirement (CTQ) Target 
Instrument/measurement quality 
Liquid Handling Robot 
Microfluidic chip 
Immunomagnetic Separation 
Microfilter 
Efficient Separation 
~92-98% purity 
>80% yield 
Automation 
Microfluidic chip 
Liquid Handling Robot 
Processing time within 30 min. 
Low whole blood input volume Microfluidic chip <10mL 
Instruments that occupy least 
space 
Microfluidic chip 
Cartridge 
Liquid Handling Robot 
No larger than desktop 
computer tower 
Cost-effective separation 
method 
Microfluidic chip 
Immunomagnetic Separation 
Microfilter 
Costs under $25 
Table 3.1: Critical-to-Quality variables 
 
3.3 Competition in the blood processing market 
 
Conventional plasma and leukocyte separation methods have relied on membrane-based filtration 
and centrifugation. Membrane-based filtration uses hydrostatic pressure to force a liquid containing the 
biomolecule mixture against a semi-permeable membrane (2, 4). However, due to high cellular fractions 
in blood, membrane-based filtration leads to clogging and compromise separation efficiency. 
Centrifugation is the process that uses centrifugal force to isolate solid suspended particles from their 
surrounding liquid media (2, 4). To separate macromolecules such as proteins and DNA, the solution 
usually runs in a special medium that separates into distinct density zones. Traditional bench-top 
centrifuges are known to be expensive, time consuming and labor intensive. In an effort to realize 
centrifugation on a microscale, disk centrifuges use compact disk-like platforms with manifolds and a 
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Figure 3.1 RTS Life Sciences ABF 200  
spinning motor plate to achieve centrifugal pumping. However, during centrifugation the sedimented 
blood cells can easily lyse, thereby releasing intracellular components that contaminate the plasma sample 
(2, 4, 5). Microfluidics has the potential to overcome these limitations. Microfluidics is the science of 
studying fluid flow behavior at the microscale and the development of miniaturized analysis systems that 
take advantage of the unique physics at these small scales (2, 4). Microfluidics leverages its many distinct 
features such as low sample volume, reduction in processing time, automation of processing steps, and 
capability to produce reliable and selective outputs. These advantages make microfluidics an attractive 
separation method for point-of-care applications and laboratories with high throughput demands. 
Currently, there are no microfluidic-based blood processing devices on the market. Our closest direct 
competitor is centrifuge-based blood processing machines, such as ones sold by RTS Life Sciences. 
 RTS Life Sciences ABF 200 is a centrifuge-based blood 
processing machine that automates the separation, storage, and 
tracking of blood samples. The machine has a proprietary signaling 
system that accurately measures the fraction heights of centrifuged 
blood in collection tubes. After calculating each volume using the 
dimensions of the tube, this information is transferred to a liquid 
handling robot to aspirate and dispense the fractions. The machine 
processes up to 500 samples a day in either 6ml or 10ml collection tubes and has dimensions of 2m x 
2.4m x 1m (2, 4-6). Per quote from sales representative at RTS Life Sciences, the ABF 200 is typically 
sold at around $700,000. 
3.4 Distinguishing Features of the Diamond HemeSep 
 
 A comparative analysis for the Diamond HemeSep and its competing products proves that the 
Diamond HemeSep is the superior product. The Diamond HemeSep delivers significant value to our 
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customers by saving time, labor, and money, while providing reproducible and high-quality results. Table 
3.3 compares major features and prices of our device against competing products.  
 One main feature of the Diamond HemeSep is the automation of the process that eliminates labor 
and saves time. By leveraging the microfluidics technology and liquid handling, the Diamond HemeSep 
can separate whole blood into the three desired components in 24 minutes, which is significantly less than 
the 60 to 90 minutes under manual processing. Furthermore, automation eliminates the need for consistent 
human involvement in the process. This allows staff resources to be better utilized and reduces costs. 
Automation also minimizes the exposure to unscreened blood and thus reduces the health risks exposed to 
staff. Under manual processing, the separated blood fractions often have highly variable purity. 
Automation overcomes this limitation and, through standardization, gives reproducible and accurate 
outputs. These advantages ultimately results in greater productivity for our customers. 
 Other distinct features of Diamond HemeSep differentiate it from competing options and appeal 
to our target customers. Unlike the competing products, the Diamond HemeSep only requires small 
volume of whole blood input while still achieving efficient separation. This feature is highly desirable in 
clinical trials where blood samples are rare, such as in the fields of neonatology and orphan diseases. As 
well, the Diamond HemeSep is highly portable and offers the convenience of a relatively small device, 
since it does not occupy more space than a desktop computer tower. Unlike competing devices, such as 
clinical laboratory centrifuges or the competing product ABF 200, the Diamond HemeSep can be used in 
new locations such as physician’s offices that have limited access to clinical laboratory facilities. This 
will allow healthcare professionals to acquire information in a timely manner. This feature is also highly 
desirable in laboratories where space is limited and real estate costs are high. Moreover, the price of our 
product is also significantly lower than the prices of competing products.  
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 Centrifuge ABF 200 Diamond HemeSep 
Exposure to Health Risks Technicians exposed 
to unscreened blood 
Minimized Minimized 
Processing time ~60-90 min. per 
10mL whole blood 
A rack of 24 
vacutainers in <5min. 
~24 min. per 5mL 
whole blood 
Labor  Labor intensive; lots 
of waiting time 
Automated Automated 
Consistent/Reproducible 
results 
No Yes Yes 
Quality results No Yes Yes 
Space Equipment and 
technicians; occupies 
most space 
2m x 2.4m x 1m 4” x 6” x 3”; 
occupies least space 
Sample Volume >10ml 6ml or 10ml <5ml 
Cost Centrifuge: ~$5000 
Labor Costs: 
significant 
>$700,000 Cartridge: <$25 
Processing Unit: 
$100,000 
Table 3.3: Quality and price comparisons between the Diamond HemeSep blood processing unit and the ABF 
200 
3.4.1 House of Quality 
 
 The House of Quality (HOQ) relates the customer requirements to the overall product 
requirements and consists of six sections. The first section is a list of the customer requirements and the 
second section lists the technical requirements associated with the customer requirements. The third 
section consists of a matrix that shows the relationships between the customer and technical requirements, 
showing whether or not the technical requirement exists for a certain customer requirement. The fourth 
section, or the top of the house, shows the synergies and conflicts among the technical requirements. In 
this section, a plus sign is used to show synergies between both variables while a minus sign is used to 
show conflicts between both variables. If no relationship exists between the variables, the space is left 
blank. The final section displays the weighting factors for the customer requirements which were already 
determined in the customer requirements table (2). 
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Figure 3.2: Diamond HemeSep Cartridge’s House of Quality Matrix
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3.5 Market Projection 
 
 All revenues in the near future of the Diamond HemeSep will come from its focus on the pre-
clinical and clinical trials market. In the future, other possible markets such as disease diagnostic or 
inflammation monitoring in surgeries will be studied. At present, sales in other markets will not be 
considered. It has been estimated that there are 1000 total clinical sites in the U.S. and that 1 million 
blood samples are processed each year. It was also assumed that the number of clinical sites and blood 
samples will grow at a rate equivalent to the growth rate of the blood industry. The average growth rate of 
the blood collection and processing industry is 5.5% (37).  
 Following development of the product, we have assumed that sales of the Diamond HemeSep can 
be maintained for 9 years. Diamond HemeSep’s market share is approximated to be 15% in the first year 
of production, growing to 30% in the second year of production, and reaching 50% in the third year of 
production. It is assumed that Diamond HemeSep will maintain this market share in the rest of production 
years. While this kind of market penetration seems ambitious, we believe that it is achievable due to the 
quality of our product and the nature of the market. We expect that the Diamond HemeSep’s automation 
of blood processing and its other features will provide significant value to clinical laboratories. Since the 
technology of our device is novel, there should be little competition. As scientists and healthcare 
professionals recognize the value of our product, the use of microfluidic-based blood processing devices 
could become a standard within the industry.  
 Based on these projections, the number of single-use Diamond HemeSep Cartridges we expect to 
sell ranges from about 160,000 in 2014 to 900,000 in 2023. Assuming 250 days of production annually 
and eight hour work days, manufacturing requirements will range from 80 to 450 cartridges per hour.  
 Sales for the processing unit were estimated based on assumptions that the processing unit has a 
product life of 10 years and that each clinical site uses one unit. Additional revenue from maintenance and 
repair services is estimated as 15% of revenue from sales of the processing units.  
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3.6 Patents 
 
 The intellectual property of the Diamond HemeSep will be limited primarily by patents held by 
Bayer Healthcare LLC. Bayer Healthcare’s patent US 7094354 B2, filed on December 19, 2002, 
describes the separation of particles using a microfluidic device (38). This should pose no major obstacles 
because the Diamond HemeSep will file new patents of novel designs of the microfluidic chip and the 
cartridge.  
3.7 Summary 
Overall, our market analysis showed that the Diamond HemeSep is an innovative 
technology with the potential to disrupt the blood processing industry. There is a significant 
unmet need for a more efficient and reliable method to fractionate blood. By leveraging its 
microfluidic technology and automation process, the Diamond HemeSep can fulfill this need. 
Currently, there are no microfluidic-based blood processing devices on the market. Thus, the 
Diamond HemeSep has the potential to realize first-mover advantages. Moreover, since it is 
portable and relatively low cost, the Diamond HemeSep offers significant value over competing 
products. Under base case assumptions, we expect to achieve sales of up to 900,000 single-use 
cartridges per year. Additional revenue streams include sales of the processing unit and 
maintenance and repair service fees.  
 Our business model will initially be targeted at the research and clinical trials market. We 
will target pharmaceuticals, biotech research and development companies, and hospital and 
clinical laboratories. Since the technology of the Diamond HemeSep is theoretically applicable 
for diagnostic uses as well, it may be possible to expand into other diagnostic markets for various 
diseases.  
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Chapter 4: Diamond HemeSep Cartridge 
4.1 Process Overview 
4.1.1 Cartridge Diagram 
 
Figure 4.1a: 2-D diagram of the Diamond HemeSep cartridge. 
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Figure 4.1b: 3-D rendition of the Diamond HemeSep cartridge. 
 Building on the principles outlined in coming chapters, this chapter describes the design 
of a cartridge to create a stabilized DNA lysate from WBCs, a plasma output and a serum output.  
We sought to design a system that emulates the reliability and reproducibility of clinical 
laboratory methods.  To do so, we designed three separate, parallel separations processes that use 
microfluidics to separate plasma from whole blood, immunoprecipitation to isolate and then lyse 
WBCs from whole blood, and a filtration system to separate serum from plasma. 
Figure 4.1a is a Microsoft PowerPoint schematic of our cartridge design.  Figure 4.1b is a 
3-D rendition of the cartridge developed in the CAD software Solidworks.  The cartridge has 
been designed to the specifications of a standard 96 well microplate for the ease of integrating its 
use with existing liquid handling technologies.  The patient’s blood sample, collected in a 5 mL 
citrated vacutainer, is loaded into the red input labeled “Blood Reservoir” on the cartridge prior 
to processing.   As described in later sections of the chapter, the original blood sample is initially 
aliquoted into samples for plasma separation and white blood cell separation.  First, 1 mL of 
whole blood is placed in well G10, where the white blood cell processing steps, described later, 
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occur in wells G10 and H10 before a final output is created and stored in the larger circle labeled 
“WBC”.  Somewhat simultaneously, the liquid handler withdraws two aliquots of 120 µL of 
whole blood from the original input and deposits the blood to wells E1 –H1.  Then the liquid 
handling robot applies a constant pressure gradient (∆P in Figure 4.1a) to maintain a blood flow 
rate of 10.5 μL/min through each of the four microfluidic bifurcations.  This occurs for a total of 
20 minutes, with brief interruptions to perform mixing steps as detailed in the WBC processing 
section.  The flow through the microfluidic chip separates the whole blood into a nearly pure 
plasma fraction in wells E5 – H5 and a waste cell, platelet and debris fraction in wells E6 – H6.  
This occurs through a phenomenon known as the Zweifach-Fung effect, described in Chapter 6.  
A more detailed CAD drawing of the microfluidic portion of the cartridge is provided later.  
After the first two aliquots of plasma have been processed, they are transferred to the serum 
processing section of the cartridge in well G8.  After calcium and thrombin have been added as 
detailed further in section 4.2.2, and the plasma has been clotted, the microfilter in G9 is used 
along with the liquid handler to remove purified serum from the plasma fractions.  The plasma 
and serum outputs will be stored in the large red circular areas labeled “Plasma” and “Serum” for 
the end-user.  
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4.1.2 Overall Process Flowsheet 
 
  
Mixing well 
(batch, 5:19)
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(batch, 7:51)
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4.1.3 White Blood Cell Processing Flowsheet 
 
 
Step 1: Machine picks up 1st tip.  Step information: (t = 2 s, tips = 1).  
Cumulative information:  (t = 2 s, tips = 1)
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Step 2: Draws up 1 mL whole blood.  Step information: (t = 2 s, tips = 0).  
Cumulative information:  (t = 4 s, tips = 1)
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Step 3: Pipette 1 mL whole blood into 1st well, put tip back.  Step information: (t = 5 s, 
tips = 0).  Cumulative information: (t = 9 s, tips = 1) 
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Step 4: Machine picks up 2nd tip, withdraws 25 μL FlowComp CD45 RA antibody.  
Step information: (t = 4 s, tips = 1).  Cumulative information:  (t = 13 s, tips = 2)
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Step 5: Machine pipettes antibody into whole blood, picks up 75 µL bead and pipettes 
into blood. Step information: (t = 6 s, tips = 1). Cumulative information:  (t = 19 s, tips 
= 2)
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Step 6: Mix for 25 s with tip, put tip back and use hand for other processes, come 
back with same tip, repeat for 5 min total.  
Step information: (t = 5 min, tips = 0).  Cumulative information: (t = 5:19 s, tips = 2) 
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Step 7: Transfer bead, antibody, blood mixture to magnetic well using the same tip.  
Let magnet concentrate WBC for 2 min
Step information: (t = 2 min, tips = 0).  Cumulative information: (t = 7:19, tips = 2) 
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Step 8: Machine picks up 3rd tip.  
Step information: (t = 3 s, tips = 1).  Cumulative information:  (t = 7:22, tips = 3)
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Step 9: Machine withdraws 0.7 mL supernatant and disposes in waste.  
Step information: (t = 6 s, tips = 0).  Cumulative information: (t = 7:28, tips = 3)
Step 10: Machine puts 3rd tip back, picks up 4th.  
Step information: (t = 5 s, tips = 1).  Cumulative information: (t = 7:33, tips = 4) 
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Step 11: Machine withdraws 0.7 mL PBS.  
Step information: (t = 2 s, tips = 0).  Cumulative information: (t = 7:35, tips = 4) 
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Step 12: Gently pipette up and down, move liquid (0.7 mL) to trash, put 4th tip back
Step information: (t = 10 s, tips = 0).  Cumulative information: (t = 7:45, tips = 4) 
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Step 13: Machine picks up 5th tip and withdraws 0.7 mL PBS
Step information: (t = 5 s, tips = 1).  Cumulative information: (t = 7:50, tips = 5) 
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Step 14: Gently pipette up and down, move liquid (0.7 mL) to trash, put 5th tip back
Step information: (t = 10 s, tips = 0).  Cumulative information: (t = 8:00,  tips = 5) 
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Step 15: Machine picks up 6th tip and withdraws 400 μL 1X Lysis buffer (Cell Signalling
Technologies)
Step information: (t = 5 s, tips = 1).  Cumulative information: (t = 8:05, tips = 6)
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uL
PBS
Magnet
1 mL
Whole 
blood
400 
uL
PBS
400 
uL
PBS
Step 16: Add buffer to  cells and pipette mix for 30 s on / off for 5 minutes
Step information: (t = 5 min, tips = 0).  Cumulative information: (t = 13:05, tips = 6)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Blood 
Reservoir 
(5 mL)
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
Microfilter
<66 ul
plasma
<66 ul
plasma
Trash
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
400 
uL
PBS
400 
uL
PBS
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Step 17: Transfer cell lysate to WBC product well
Step information: (t = 5 s, tips = 0).  Cumulative information: (t = 13:10, tips = 6) 
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Blood 
Reservoir 
(5 mL)
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
Microfilter
<66 ul
plasma
<66 ul
plasma
Trash
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
400 
uL
PBS
400 
uL
PBS
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4.1.4 Plasma and Serum Processing Steps 
 
 
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
1 mL
Whole 
blood
Step 1: Pick up tip, transfer 120 ul of plasma into 4 wells on microfluidic chip, and put tip 
back. Step information: (t = 18 s, tips = 0).  Cumulative information: (t = 0:18, tips = 1)
5 ml 
whole 
blood
Step 2: Bifurcation Process – Run for total of 20 minutes at a flow rate of 10 µL/min.  
Step information: (t = 20:00, tips = 0).  Cumulative information (t = 20:18, tips = 1)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
Microfilter
<66 ul
plasma
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
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Step 3: Pick up tip, transfer <66μL plasma into well for serum separation, return tip.  
Step information: (t = 0:12, tips = 1). Cumulative information: (t = 20:30, tips = 2)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
Step 4: Pick up tip, add 10 μL .05mg/mL thrombin and 10 μL 3.5 M calcium.  Step 
information: (t = 0:06, tips = 1).  Cumulative information: (t = 20:36, tips = 3)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
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Step 5: Use tip to gently mix.  Step information: (t = 0:10, tips = 0).  Cumulative 
information (t = 20:46, tips = 3)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
Step 6: Transfer solution to well with microfilter, return tip.  Step information (t = 0:06, 
tips = 0).  Cumulative information (t = 20:52, tips = 3)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
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Step 7: Use liquid handler to push solution through filter.  Step information (t = 0:06, 
tips = 0). Cumulative information (t = 20:58, tips = 3)
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
Step 8: Pick up tip, transfer serum to serum product well, return tip.  Step information: 
(t = 0:09, tips = 1).  Cumulative information (t = 21:07, tips = 4).
A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
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A
B
C
H
D
E
F
G
1 32 4 5 6 107 128 119
Tips
WBC
Plasma
Serum120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
120 ul
whole 
blood
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
<66 ul
plasma
50 µL 
CD45RA 
ab
100 µL 
dynabead
400 
uL
PBS
400 
uL
PBS
300 
µL 
Lysis
Ca+2 
Thrombin
Blood 
Cells
Blood 
Cells
Blood 
Cells
Blood 
Cells
Microfilter
<66 ul
plasma
Trash
400 
uL
PBS
300 
µL 
Lysis
400 
uL
PBS
Magnet
1 mL
Whole 
blood
Step 9: Pick up tip, transfer plasma to plasma product well, return tip. Step 
information (t = 0:09, tips = 1).  Cumulative information
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4.1.5 Process Scheduling 
 
In addition to a Gantt chart for the on-cartridge processing steps shown in Figure 4.2, 
Tables 4.1 and 4.2 display the exact timing, number of wells/tubes and tips involved in each 
separation unit’s steps.  This timing was calculated based on channel dimensions as well as the 
volumes of reagents needed to try and design a cartridge that had a total processing time of under 
30 minutes.  It should be noted that the timing displayed in the tables is the time required by each 
of the separation units and not the actual cumulative time since the start of cartridge operation.  
The Gantt chart displays the real time sequential scheduling of when the liquid handling unit is 
occupied by each of the separation processes. 
The liquid handling unit pauses during the microfluidic plasma separation, allowing it to 
be used to perform mixing steps in the white blood cell processing sequence.  Experimentally, 
we observed that such starting and stopping of the applied pressure to the microfluidic device 
does not interrupt flow through the channels for gaps smaller than approximately 1 minute.  This 
advantageous feature of the microfluidic chip allows parallel processing to occur on the 
cartridge, expediting the total amount of time required to generate the three outputs.
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Figure 4.2: Gantt Chart Displaying Liquid Handler Scheduling During Various Separation Processes
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Table 4.1: White Blood Cell Processing Steps 
  
Step Description Tube/Step Tips/Step Time/step Cumulative Tubes Cumulative Tips Cumulative Time
1 Machine picks up 1st tip 0 1 0:02 0 1 0:02
2 Draw 1 mL whole blood 0 0 0:02 0 1 0:04
3
Pipette 1 mL whole blood into 1st 
well, put tip back
1 0 0:05 1 1 0:09
4
Machine picks up 2nd tip, withdraws 
25 uL antibody
0 1 0:04 1 2 0:13
5
Machine pipettes ab into whole 
blood, picks up 75 uL beads and 
pipettes into blood
0 0 0:06 1 2 0:19
6
Mix 25 s with tip, put tip back, use 
hand for other process, come back 
with same tip, repeat 5 min
0 0 5:00 1 2 5:19
7
Transfer bead, ab, blood to magnetic 
well using same tip, let magnet 
concentrate
1 0 2:00 2 2 7:19
8 Machine picks up 3rd tip 0 1 0:03 2 3 7:22
9
Machine withdraws 0.7 mL 
supernatant and disposes in waste
0 0 0:06 2 3 7:28
10
Machine puts 3rd tip back, picks up 
4th
0 1 0:05 2 4 7:33
11 Machine withrdaws 0.7 mL PBS 0 0 0:02 2 4 7:35
12
Gently pipette up and down, move 
liquid (0.7 mL) to trash, put 4th tip 
back
0 0 0:10 2 4 7:45
13
Machine picks up 5th tip, withdraws 
0.7 mL PBS
0 1 0:05 2 5 7:50
14
Gently pipette up and down, move 
liquid (0.7 mL) to trash, put 5th tip 
back
0 0 0:10 2 5 8:00
15
Machine picks up 6th tip, withdraws 
400 uL 1X lysis buffer
0 1 0:05 2 6 8:05
16
Add buffer to cells and pipette mix 
30 s on/off for 5 min
0 0 5:00 2 6 13:05
17
Transfer cell lysate to WBC product 
well
1 0 0:05 3 6 13:10
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Table 4.2: Plasma and Serum Processing Steps 
  
Step Description Tube/Step Tips/Step Time/step Cumulative Tubes Cumulative Tips Cumulative Time
1
Pick up tip, transfer 120 ul of  plasma 
into 4 wells on microfluidic chip, and 
put tip back
4 1 0:18 4 1 0:18
2 Bifurcation Process 0 0 20:00 4 1 20:18
3
Pick up tip, transfer 200 μL plasma 
into another well for serum 
separation process, return tip 
3 1 0:12 7 2 20:30
4
Pick up tip, add 10 µL thrombin and 
10 µL calcium 
0 1 0:06 7 3 20:36
5 Let reagents sit in plasma 0 0 1:40 7 3 22:16
6
Transfer soln. to well with microfilter, 
return tip
1 0 0:06 8 3 22:22
7 Let reagents/plasma sit in filter 0 0 1:40 8 3 24:02
8
Use liquid handler to push solution 
through filter
0 0 0:06 8 3 24:08
9
Pick up tip, transfer serum to serum 
product well, return tip
1 1 0:09 9 4 24:17
10
Pick up tip, transfer plasma to plasma 
product well, return tip
1 1 0:09 10 5 24:28
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4.1.6 Flow through the Microfluidic Chip 
 
To determine the optimal microfluidic design for our plasma separation, six different 
geometries were designed in the 2-D CAD software Solidworks and are shown in Figure 4.3 
below.  Each of the six geometries was tested in COMSOL to ensure that they met the required 
4:1 flow rate ratio as described in Chapter 6.  For simplicity, only one bifurcation channel was 
modeled, although one design incorporated three bifurcation channels.   After experimental 
testing, design 2 was selected as the optimal design, with a main channel width of 60 µm and a 
daughter channel width of 15 µm and a constant depth of 35 µm.  
 
Figure 4.3:  Six microfluidic designs constructed in 2-D Solidworks. 
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4.1.7 Process Conditions and Reagent Volume 
 
 All reagents should be stored at -80 °C until the cartridge is in use.  This measure is 
intended to preserve biological reagents such as thrombin and the antibodies.  Reagents such as 
the calcium and lysis buffer are stable indefinitely at room temperature, but for convenience, 
may be stored in the cartridge insert with the other reagents at -80 °C. 
 Thrombin must be rehydrated from its powdered stored form in TBS to obtain a final 
concentration of 0.05 mg thrombin/mL.  This should be done by the user immediately prior to 
use of the cartridge. 
 The process occurs at room temperature with flow rates as specified elsewhere in and 
according to the scheduling presented in this chapter.  Reagent volumes are defined on the 
cartridge layout. 
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4.2 Microfluidic Channel Design 
4.2.1 Introduction to COMSOL 
 
COMSOL Multiphysics is a finite element analysis package that can be used to simulate 
various physics and engineering problems.  It has various physics models, namely one for creep 
flow (NRe << 1) that we used for optimizing our design prior to fabricating a prototype. 
4.2.2 Design Strategy Using COMSOL 
Objective 
 Based on the principles 
discussed in Chapter 6, we used 
COMSOL’s geometry tools to design a 
main channel that split into three 
daughter channels as shown in Figure 
4.4.  Our objective was to design a 
system in which the ratio of the flow rates through the smaller daughter channels to the flow 
rates through the larger main channel was at least 4.0.  As discussed in Chapter 6, this situation 
has been shown to be optimal for nearly pure separation of plasma from the other blood 
components (3).   
We were able to approximate the design as two dimensional using COMSOL’s shallow 
channel approximation.  Due to manufacturing limitations, we were able to design a channel with 
a minimum thickness of 45 µm. 
Boundary Conditions & Other Specifications 
 COMSOL was used to determine steady state operation of the device.  An inlet condition 
corresponding to the inlet on the left hand side of Figure 4.4 was set to 10.5 µL/min.  The four 
outlets on the right hand side of Figure 4.4 were set to an outlet pressure of 1 atm.  The material 
Figure 4.4:  Microfluidic design geometry. 
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through the entire device was approximated as water, although blood is known to have a slightly 
higher viscosity (~5 – 10 cP) than that of water (~1 cP).  This assumption was justified since 
plasma is 93% water by volume and the ratio of viscosities of blood and water is under ten.  
Therefore, we assumed this approximation introduced negligible error while allowing us to 
grossly simplify the simulation.  After this, the simulation was run to determine steady state 
conditions through each section of the microfluidic device. 
Analysis of the Results 
 Results were analyzed primarily to determine the ratio of the flow rate through the 
daughter channel to the flow rate through the main channel for each bifurcation.  To this effect, 
COMSOL was used to determine the average velocity through the daughter channel and main 
channel through each bifurcation.  The flow rate through a channel is most generally expressed 
by Equation 4.1, below where Q is the channel’s volumetric flow rate, u is the linear velocity 
through the channel and Across sectional is the cross sectional area of the channel. 
                      (4.1) 
Furthermore, the cross sectional area of a rectangular channel is given by Equation 4.2 
where Hchannel is the height of the channel in the y-axis direction in Figure 4.4 and Tchannel is the 
thickness of the channel in the z-axis (not shown), which was constant for all parts of the device 
at 35 µm. 
                                    (4.2) 
 Since the thickness of the channel was constant for the device, the ratio of two flow rates 
could be expressed by Equation 4.3. 
 
  
  
 
    
    
 (4.3) 
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 This relationship was used to determine the flow rate ratios for a variety of geometries, 
some of which are displayed for the reader in the subsequent section. 
4.2.3 Results of COMSOL Simulations 
 
  Main u [m/s] Daughter u [m/s] Ratio 
First Bifurcation 0.047 0.069 1.59 
Second Bifurcation 0.031 0.039 1.89 
Third Bifurcation 0.024 0.018 3.17 
Table 4.3: Ratios for a channel thickness of 10 µm, a daughter height of 15 µm and a main width of 35 µm 
  Main u [m/s] Daughter u [m/s] Ratio 
First Bifurcation 0.054 0.079 1.57 
Second Bifurcation 0.040 0.048 1.94 
Third Bifurcation 0.032 0.023 3.17 
Table 4.4: Ratios for a channel thickness of 10 µm, a daughter height of 15 µm and a main width of 50 µm 
  Main u [m/s] Daughter u [m/s] Ratio 
First Bifurcation 0.071 0.043 3.88 
Second Bifurcation 0.064 0.028 5.27 
Third Bifurcation 0.061 0.015 9.50 
Table 4.5: Ratios for a channel thickness of 35 µm, a daughter height of 15 µm and a main width of 60 µm 
  Main u [m/s] Daughter u [m/s] Ratio 
First Bifurcation 0.064 0.053 2.84 
Second Bifurcation 0.053 0.034 3.69 
Third Bifurcation 0.048 0.017 6.53 
Table 4.6: Ratios for a channel thickness of 35 µm, a daughter height of 20 µm and a main width of 60 µm 
For a channel thickness of 35 µm and for a main channel height of 60 µm and daughter channel 
height of 15 µm (the design we actually implemented), Figure 4.5 below graphically depicts the 
flow pattern 
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Figure 4.5: COMSOL velocity profile for microfluidic design geoemtry. 
 
4.3 Serum Filter Design 
 
We considered several designs for the filter unit.  Initially, a design in which the filter is 
internal to the pipette was favored.  However, we decided that keeping the filter on the actual 
cartridge fit our needs best.  The design of the filter seen in Figure 4.6 is based off of a standard 
U-bottom 96 well plate.  The membrane and backing is located at the bottom of the well where 
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the U-bottom begins.  The walls of the plate are slightly narrower here to provide extra support 
to the membrane.  At the top of the well is a simple rubber septum which has been punctured to 
allow the pipette to enter the well.  This will provide a seal as the pipette enters the well.  This 
also has a plastic backing to provide additional support.  The filtered serum collects in a 
neighboring hood.   
 The filtering process begins with the transfer of plasma with clotting factors into the well 
before the gel point has been reached.  After this has fully clotted, the pipette again enters the 
well and pushes at 50 psi for 5 seconds.  As the serum is pushed through the filter, it will flow 
Figure 4.6:  Cross section of the filter.  All numbers have units of mm 
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into the neighboring well, which is positioned slightly below the filter well to reduce holdup.  
With a new tip, the fluid handler withdraws the serum from the neighboring well and transfers it 
to the final serum container.    
 The scheduling of the serum filtration is derived from the kinetics of the clotting reaction.  
Luckily the kinetics of this complex series of reactions 
has been studied extensively (7).  Multiple species are 
created in multiple reactions, the rates of which impact the 
overall structure and properties of the resulting clot.  
Although multiple factors have an effect on the rate of this 
reaction, the two most important for us are the fibrinogen 
and thrombin concentration.  Thrombin concentration has 
an effect on the rate of coagulation, up to a maximum 
concentration of 0.1 NIH unit/mL (an NIH unit is an 
arbitrary measure of catalytic activity of an enzyme).  At this point, an increase in the 
concentration of thrombin does not appreciably accelerate the rate of reaction (Figure 4.7).  Thus 
we chose to use a concentration of 1 NIH unit/mL thrombin.  In addition, CaCl2 is added, as it is 
essential for thrombin to function properly.  
 In our separation we hope to both have a complete clot as quickly as possible, and to 
consume all of the fibrinogen and protofibrils.  As shown in Figure 4.8, this is accomplished by 
letting the reaction proceed for about 225 seconds.  We broke this into two sections for two 
reasons.  First, since fibrinogen and protofibrils are relatively small species, allowing the plasma 
to sit in the filter for the full 225 seconds before filtering could allow some of the fibrinogen and 
protofibrils to filter through with gravity as the driving force.  By transferring to the filter after 
Figure 4.7: Turbidity indicating the 
progression of clot formation at thrombin 
concentrations of 1) 1 NIH unit/mL 2) 
.01unit/mL  3)  0.01 unit/mL and 4) 0.001 
unit/mL.  The rates of 1 and 2 are nearly 
identical, with 3 and 4 being significantly 
slower 
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100 seconds of clotting, all 
of the fibrinogen and most 
of the protofibrils will be 
consumed, but the plasma 
will not have reached the 
gel phase yet.  Second, this 
transfer step will mix the 
plasma, which will 
hopefully speed the reaction.   
4.4 Experimental Data from Prototype Microfluidic Device 
 
4.4.1: Experimental Design and Purpose 
 
 A prototype of the microfluidic chip of 
our cartridge was built in a manner similar to the 
soft photolithography previously described.  A 
photomask was designed in Solidworks and 
printed in high resolution (10,000 DPI).  Then, a 
negative photoresist was spun onto a silicon 
wafer at 4000 RPM for 30 seconds to achieve a 
thickness of 45 µm.  Following a soft bake at 95 °C 
for 15 minutes, the wafer was aligned with the 
printed photomask in a Karl Suss mask aligner and exposed to 365 nm UV light to achieve 975 
mJ/cm
2
 of exposure energy.  Afterwards, a post exposure bake occurred at 95 °C for 3 minutes 
and all un-reacted photoresist was removed with a developer for 10 minutes under frequent 
Figure 4.8 
Figure 4.9: Fabricated PDMS microfluidic 
chip attached to a glass slide.  As shown here, 
a clear plasma fraction (right) and 
concentrated blood ouput (red droplet, left) 
can be oserved. 
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agitation.  Then, in a mixture of 1:10 mixture of PDMS and curing agent was poured into the 
mask and placed into an 80 °C oven for 2 hours.  After this step, the device was removed, cut, 
sealed to a glass slide, and ports were punched to allow for outlet collection and pressure input. 
 The main intention of this testing was for proof of concept purposes.  The chip included 
six total designs with the same channel dimensions, but different types of bifurcations (as shown 
in Figure 4.9).  All of these designs had a main channel width of 60 µm, a daughter channel 
width of 15 µm and a depth of 45 µm.  The same flow rates and fabrication process was used as 
would have been for the complete device shown in previous figures.  Therefore, testing was 
intended to demonstrate three things: 1) that the chip design was capable of being manufactured, 
2) that the microfluidic principles underlying the design were effective at separating blood and 3) 
that the flowrates being used would be sufficient without either destroying the device or causing 
shear of the blood cells. 
 It should be noted that there were a few important differences between the testing and the 
way the cartridge will work in the liquid handling unit.  First, lab equipment was used to 
substitute functions the liquid handler would normally perform.  The liquid handling robotic arm 
was substituted with a syringe pump from Harvard Apparatus in order to apply a constant flow 
rate (from 10 µL/min to 25 µL/min during testing) across the channels.  Blood was collected in a 
citrated tube from a willing volunteer and then placed in a syringe to be pumped through the 
device.  Flow rates ranging from 10 µL/min to 25 µL/min were tested through each of the six 
designs.  The chip was mounted on an inverted microscope so that pictures of the device in 
action could be obtained.  Initial trials using the device without modification and with whole 
blood showed no plasma separation under any flow rates.  However, subsequent trials aimed at 
increasing the resistance to flow through the plasma channels demonstrated that the device does 
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indeed fractionate the blood into a plasma fraction and a remaining blood fraction.  These results 
are discussed next. 
4.4.2 Preliminary Qualitative Results 
 The device was first viewed under the microscope to ascertain whether or not the 
fabrication process maintained structural fidelity to the SolidWorks mask (Figure 4.3) we 
designed.  The figures below examine some of the various designs to demonstrate that, indeed, 
the channels maintained their structural accuracy through the soft photolithography process.  In 
the figures below, three designs are examined, a 3-channel bifurcation with rounded square 
edges, an angled bifurcation and a “y” bifurcation (a-c, respectively). 
 
Figure 4.10: A – three bifurcations in series with rounded square edges.  B – a single, angled bifurcation 
pattern.  C – a single “y” shaped bifurcation pattern 
 As mentioned earlier, initial trials of running the device with human whole blood did not 
work under any flow rates.  The blood simply split its flow but stayed as whole blood as it 
flowed through the channel.  No images were taken of this process 
 Furthermore, it was observed that for flow rates up to 15 µL/min, no blood shearing was 
observed, indicating that the process could potentially be made faster during year of clinical 
testing. Under dilution of the whole blood to 10% hematocrit, flow rates up to 25 µL/min could 
be achieved. 
 Finally, preliminary testing showed that removal of the syringe pump pressure did not 
immediately stop flow, because of the pressure buildup in the channels associated with 
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microfluidic flow.  This observation is critical to correct operation of the device in the cartridge 
as shown in the Gantt chart, since the liquid handling unit must take breaks from pushing the 
fluid through the microfluidic chip in order to perform parallel mixing steps. 
4.4.3 Troubleshooting and Further Qualitative Results 
 
 Taken together with our outputs from the COMSOL simulation, preliminary 
experimental results suggested that some of the assumptions inherent in our COMSOL model 
were incorrect, resulting in a flow pattern that was not conducive to plasma skimming.  Namely, 
our COMSOL model approximated the 
material properties of blood as those of 
water.  While the viscosities are similar, 
since blood is 93% water by volume, this 
approximation most likely introduced an 
error into calculating the ratio of resistances 
through the daughter channels after the 
bifurcation.  Since it is this ratio that 
governs how the blood will split into plasma and cell/particulate fractions, any calculation errors 
manifested physically in a flow pattern that did not cause separation of the blood.  Furthermore, 
the material was assumed to be constant throughout the device domain for the purposes of 
simplifying the COMSOL simulation.  Again, though the viscosities of plasma and the 
concentrated blood fraction are similar, they are not the same, introducing further error in the 
resistance calculations.  Finally, the COMSOL model did not take into account the total length of 
the device in calculating resistances and pressure drops.  In normal industry applications where 
turbulent flow is common, the effect of pipe length is usually negligible.  However, in 
Figure 4.11: Flow through a longer path length channel 
with a width of 250 µm produced concentrated plasma 
towards the channel edges near the channel outlet.  This 
phenomenon could prove useful in designing a chip to 
"skim" plasma from whole blood. 
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microfluidics, where creep flow is prevalent, the effect of total channel length is likely not 
negligible.   
This suggestion is backed up by the following experimental evidence.  We tested an 
existing microfluidic device with a total path length of almost 10 cm (in comparison to the 1-2 
cm path lengths in our prototype).  Though the channel width was approximately 250 µm, 
making direct comparison with our designs difficult, flow was examined at the outlet of the 
channel.  As can be seen in Figure 4.11, plasma seems to concentrate towards the edges of the 
wall while blood cells migrate towards the center of the flow profile.  Future designs could take 
advantage of this phenomenon through a three way channel split to skim plasma from the 
remainder of whole blood. 
Next, we placed a 100 µL droplet of water at the outlet of the plasma channel on our 
prototype design with the intention of providing a hydrostatic pressure head to increase 
resistance to flow through that channel.  This was done for a few different bifurcation styles.  
Assuming a completely spherical drop and a density of 1 g/cm
3
, this droplet corresponded to a 
pressure head given by Equations (4.1) and (4.5): 
           (
 
 
)                   (4.4)   
                  (4.5) 
 This additional pressure head was sufficient to effect separation of plasma from whole 
blood as shown in Figure 4.12 below. 
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Figure 4.12: A - angled bifurcation working under increased hydrostatic pressure on plasma channel.  B - 
rounded square bifurcation working under increased hydrostatic pressure.  C - rounded bifurcation in final 
design working under increased hydrostatic pressure 
The results of this set of experiments fairly conclusively demonstrate that indeed, the 
bifurcation principle should hold.  Unfortunately, the simplifying assumptions in our COMSOL 
model did not allow for the correct calculations of the resistance ratios.  However, knowing this 
a priori would have been fairly difficult, and with empirical data to help uncover this flaw, the 
model can be updated and the design improved during the clinical trial year. 
Blood smears were taken for the outputs of both plasma and whole blood to determine 
the purity of the plasma fraction obtained.  As can be seen in Figure 4.13, the plasma output (A) 
has considerably fewer blood cells than the blood output (B) from the channel.  Qualitatively, 
this demonstrates that the technique is suitable for use in separating plasma from whole blood. 
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Figure 1: A - plasma output from device.  A nearly pure plasma fraction (free of cells and other blood debris) 
is obtained.  B - blood ouptut from device contains considerably more cells and other debris from whole blood 
Thus, all experimental data adequately supports the aforementioned proof of concept points.  With minor 
modifications based upon the results of the experiments, the device should be able to be produced in a 
manner that successfully accomplishes the point of the product while maintaining the size and costs of the 
device mentioned here in the report. 
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Chapter 5: Blood Composition 
 
5.1 Introduction 
 
Germane to understanding the point of the Diamond HemeSep is a working knowledge of 
the biology and composition of human whole blood.  To provide such a basis, this chapter 
presents a very simple introduction to the topic. 
Human whole blood is an important bodily fluid that 
delivers oxygen and nutrients while removing metabolic waste from 
the cells and tissues of the body.  Blood is composed of three 
primary constituents as shown in Figure 5.1: 1) red blood cells 
(erythrocytes), 2) white blood cells (leukocytes) suspended in a 
liquid 3) plasma.  Hematocrit, which is defined as the percentage of 
red blood cells by volume in whole blood, is typically around 45% 
in humans (8).  The three components of blood will be discussed 
next.  
 
5.2 Plasma 
 
Human blood cells are suspended in a straw-colored liquid component of blood known as 
plasma.  Plasma, which is mostly water (93% by volume), also contains dissolved chemical 
species.  Primarily, plasma transports glucose, clotting factors, minerals, ions, hormones, carbon 
dioxide, and proteins such as albumin.  As such, plasma serves as a major protein reserve in the 
body and also as the major medium for waste removal.  Plasma constitutes around 55% of whole 
blood by volume (8, 9). 
Figure 5.1: Human whole 
blood is composed of three 
fractions: plasma, white blood 
cells (leukocytes) and red 
blood cells (erythrocytes) (8) 
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Because of its crucial role in regulating blood osmolarity and infection prevention, 
plasma is often analyzed for its salt and protein concentrations both clinically and in research.  
Consequently, obtaining nearly pure plasma fractions is very important. 
5.3 Serum 
 
Blood serum is essentially blood plasma with fibrinogens (proteins used in the clotting 
process) removed.  Serum does not contain any blood cells, but does contain all of the proteins 
not used in the clotting process and otherwise found in the plasma.  Like blood plasma, serum is 
used in many diagnostic tests both clinically and in research (10). 
5.4 White Blood Cells 
 
 White blood cells (WBCs), or leukocytes, are the 
DNA-containing blood cells that make up the body’s 
immune system.  These cells protect the body from 
infectious disease and foreign agents while also 
modulating inflammatory responses.  Five different types 
of WBCs exist: neutrophils, eosinophils, basophils, 
lymphocytes and monocytes.  The first three are classified 
as granulocytes due to their granular appearance under the 
microscope caused by membrane bound enzymes that 
engulf and destroy foreign matter.  The latter two are characterized as agranular due to the 
absence of granular appearance under the microscope (9, 11).  
Analysis of white blood cells is useful and necessary in understanding the DNA profile of 
a patient and in looking for various markers of disease and health. 
Figure 5.2: WBCs are the irregularly 
shaped spherical cells whereas RBCs 
cells are the larger, donut shaped 
cells. (9) 
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5.5 Red Blood Cells 
 
 Red blood cells (RBCs), or erythrocytes, are the most common type of blood cell.  RBCs 
deliver oxygen (O2) to the body’s cells and tissues.  These cells owe their red appearance and 
ability to transport O2 to hemoglobin, an iron containing biomolecule.  These cells develop in the 
bone marrow and circulate for about 100-200 days before being recycled and regenerated.  RBCs 
are anucleate, meaning they do not contain a nucleus and, consequently, do not contain DNA.  
Per microliter of whole blood, there are roughly 4-6 x 10
6
 RBCs. 
 RBCs are generated through a process known as erythropoiesis.  They are produced in 
the bone marrow at a rate of about 2 million cells per second and mature over seven days (12, 
13). 
5.6 Blood Coagulation 
 
Blood coagulation is the process to form a 
clot to quickly prevent excessive blood loss after 
injury.  While a quick response is essential, the 
process must not make clots that impede normal 
blood flow.  Thus the process is highly regulated by 
multiple positive and negative feedback loops.  
There are two pathways in the coagulation cascade 
(14).  Most important in vivo is the extrinsic pathway 
in which injury pushes tissue factor from surrounding 
subendothelial cells into the blood flow, initiating the 
cascade.  The intrinsic pathway, however, is much 
more important for our purposes.  This pathway is activated by an anionic surface such as glass 
Figure 5.3: Plasma coagulation. Roman numerals 
indicate unactivated coagulation factors, and 
activated factors are indicated by a lower case “a”. 
Nonenzymatic cofactors are indicated by numerals 
in black ovals. White arrows indicate reactions of 
the intrinsic pathway 
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(15).  Contact with an anionic surface produces the active serine protease XIIa from the inactive 
form XII.  This protease then selectively hydrolyses a portion of the inactive serine protease 
factor XI to form the active protease XIa.  This in turn activates factor IX in the same way, 
which then activates thrombin from prothrombin in the same way.  While the rest of the enzyme 
factors are involved primarily in regulating coagulation, thrombin is the serine protease actually 
responsible for the formation of the clot.  It is important to note that many of these factors, and 
specifically the interaction of XII with an anionic surface, depend on the presence of calcium 
ions.  Removal of calcium ions with a chelator such as EDTA or citrate prevents the coagulation 
cascade.   
 Essential in any discussion of blood 
coagulation is the final product: a blood clot or 
thrombus.  There are two main components of 
any blood clot.  First is an insoluble fibrin 
polymer, produced from the soluble protein 
monomer fibrinogen.  An electron micrograph of 
such a clot can be seen in Figure 5.4 (7).  This 
polymer can vary in its properties depending on 
the degree of branching and the thickness of the 
individual fibers.  The second component is 
blood platelets.  Platelets are cell fragments about 
a quarter of the size of red blood cells.  These become ensnared in the network of fibrin and help 
plug the flow of blood.  Finally, small amounts of the other clotting factors become stuck in the 
clot as well.  This helps to down-regulate the coagulation response and limit it to the site of the 
500 nm 
Figure 5.4: Electron micrograph of a blood clot with 
bar indicating 500nm 
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injury.  By removing these clotting factors, the production of thrombin and then fibrin monomer 
cease. 
5.7 Fibrin Polymerization 
 
 The most important process in the coagulation cascade 
for our purposes is the polymerization of fibrinogen to form 
fibrin.  This is a complex process catalyzed by the 
serine protease thrombin.  Fibrinogen circulates as a 
dimer of three chains (AαBβγ)2 which are connected 
by a disulfide bond.  Figure 5.5b shows a crystal 
structure of the A chain of the fibrinogen monomer 
(16).  The first step in the formation of the insoluble 
fibrin clot is the cleavage of part of the Aα chain by 
thrombin to form fibrin I monomers.  The fibrinogen-
thrombin complex is shown in figure 5.5a (17).  These monomers then aggregate to form fibrin I 
protofibrils.  Third, thrombin cleaves a portion of the Bβ chain to form fibrin II protofibrils.  
Finally, these protofibrils rapidly aggregate to form the insoluble fibrin clot.   
5.8 Summary 
 
 Human whole blood is composed of three main components: 1) red blood cells, 2) white 
blood cells and 3) plasma.  The cells are suspended in plasma, the major liquid fraction of whole 
blood that also contains many other dissolved species.  Blood serum is simply plasma with the 
fibrinogens clotted out and separated from the rest of the plasma.  Each of these blood fractions 
Figure 5.5: a) crystal structure of a portion of fibrin bound 
to the active site of thrombin. b) crystal structure of fibrin. 
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is diagnostically useful in its own right, making blood separation an interesting, essential process 
both clinically and in research.  
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Chapter 6: Plasma Separation via Microfluidic Design 
6.1 Introduction 
 
To induce plasma separation from whole blood without the use of traditional 
centrifugation techniques, a microfluidic channel design was implemented based on published 
work by Yang, Undar, and Zahn (3).  There are many advantages of utilizing microfluidics over 
centrifugation, including cost, size, and autonomy of the unit.  The efficacy of the device in 
separating cells from plasma in whole blood stems from the bifurcation law, or the Zweifach-
Fung Effect. 
6.2 Bifurcation Law (Zweifach-Fung Effect) 
 
 The bifurcation law states that when red blood cells encounter a bifurcation in a capillary 
blood vessel, a large number of cells flow into the daughter vessel that has the higher flow rate, 
leaving only a small number of cells to flow into the daughter vessel with the lower flow rate.  
This occurs due to the large pressure gradient of the high-flow vessel compared to the low-flow 
vessel.  Asymmetric shear stresses on the capillary walls also induce a torque on the cell that 
causes it to flow into the high-flow vessel.  It has been shown that a flow ratio of 2.5:1 is 
sufficient to induce this law in channels whose dimensions are approximately the same as a cell.  
This preferential bifurcation only occurs, however, when a cell’s centroid falls above a critical 
streamline, the stagnation point of the bifurcation.  As the ratio of flow in the daughter vessels is 
increased, this stagnation point lies closer to the low-flow vessel and effects of this law are more 
pronounced.  Figure 6.1a below diagrams the effects of pressure and shear rate on the bifurcation 
law while Figure 6.1b describes the critical streamline needed for this preferential bifurcation.  
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Figure 6.1. Schematic of the bifurcation law (Zweifach-Fung Effect) (3).  Figure 1a. shows the effect of 
pressure drop differences on the cell (ΔPh > ΔPl).  The shear rate differences (γcell_wall_high_flow > γcell_wall_low_flow) 
are also presented and are instrumental in producing the Zweifach-Fung Effect.  Figure 1b. shows the critical 
streamline in a bifurcation channel operating at a 4:1 flow rate ratio and the resulting paths of the cells.  
Path’s I and III both flow to the high-flow channel because the centroid of the cell lines above the stagnation 
streamline.  Path II, however, flows into the low-flow channel. 
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6.3 Flow rate ratio optimization 
 
 As mentioned above, the choice of flow rate ratio between the daughter channels is a key 
design specification in achieving desired separation efficiencies.  For use in research 
applications, the purity of the plasma should be as high as possible without sacrificing its 
integrity.  Yang, Undar, and Zahn show in their research that a 4:1 flow ratio between the 
channels resulted in a 98.9% recovery efficiency for C8161 Human melanoma cells while ratios 
above 6:1 resulted in 100% efficiency (3).  Their complete analysis is shown in Figure 6.2 
below. 
 
Figure 6.2. Recovery efficiency of 16 um fluorescent particles and 8-10 um C8161 Human melanoma cells.  It 
can be seen that at flow ratios greater than 4:1 cell recovery efficiency is virtually 100%.  Cell efficiency was 
consistently greater than the fluorescent particles because the deformity of the cell led to an asymmetric 
distribution of cells in the middle of the channel, which increased efficiency (3). 
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6.4 Flow rate resistance and use of multiple parallel bifurcations  
 
 To achieve greater plasma yields in the microfluidic device, multiple parallel bifurcations 
can be incorporated.  However, each additional channel causes a drop in flow resistance in the 
subsequent channels.  To prevent efficiency losses in the subsequent channels, each channel 
diameter must be changed to reflect this.  Equation 6.1 below demonstrates the relationship 
between pressure changes (ΔP), flow rates (Q), and resistance to flow (R): 
        (6.1) 
From this equation it is seen that flow resistances will need to be varied to achieve the desired 
pressure changes.  These resistances must therefore satisfy the following equation: 
             
 
     
            (6.2) 
Where rQ is the flow rate ratio, Rp,j is the resistance of the j
th
 plasma channel, and RB,j is the 
resistance of the j
th
 blood cell channel.  Yang, Undar, and Zahn performed their analysis on a 
microfluidic design that incorporated 5 daughter plasma channels.  Figure 6.3 below reproduces 
their velocity profiles and analytical results from using computational fluid dynamics. 
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Figure 6.3a. CFD velocity profile for microfluidic device. Each split results in a decreasing velocity profile. 
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Figure 6.3b.  Velocity magnitude at each node for varying channel widths.  As blood flows downstream the 
velocity magnitude decreases proportionally, and the parabolic peak represents the optimal channel width. 
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Figure 6.3c.  Flow rate ratio for 1%,5%,15,45% hematocrit using CFD analysis.  Bifurcation nodes farther 
downstream result in larger flow rate ratios. 
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6.5 Overall device efficiency and the Fahreus effect 
 
To test the overall efficiency of the microfluidic device, the percent by volume of plasma 
separated is quantified.  This value (η) can be expressed with the following equation: 
      {  (
   
   
   ) (
   
       
)   
   
   
}  (6.3) 
Where Hmu is the hematocrit levels upstream of the separation region and Hmd is the hematocrit 
levels downstream of the separation region.  When a higher initial inlet hematocrit is used, 
higher upstream and downstream hematocrit levels are observed.  These simultaneous increases 
lead to higher percent by volume plasma separation, as seen in Equation 6.3.  Yang, Undar, and 
Zahn quantitatively confirmed Equation 6.3, and the results are reproduced in Figure 6.4 below.  
It has been shown, however, that when a large feed inlet is flown into a channel of smaller 
diameter, the average hematocrit decreases as channel diameter decreases.  This is known as the 
Fahreus effect and is shown for a 15 µm channel in Figure 6.5 below (3).   
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Figure 6.2. Microchannel hematocrit vs. time for inlet hematocrit levels of 10% and 35%.  4(a) represents 
inlet levels of 10% and 4(b) represents inlet levels of 35%.  As inlet hematocrit levels increase, the degree of 
separation is increased, as expected from Equation6. 3. 
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Figure 6.3.  Fahreus effect in a 15um microchannel.  As inlet hematocrit increases, upstream hematocrit 
increases. 
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Chapter 7: White Blood Cell Separation via Immunomagnetic 
Precipitation 
7.1 Introduction 
 
As described in Chapter 5, leukocytes are the only DNA containing cells in human whole 
blood.  Therefore, it is often of interest to a clinician or researcher to analyze the DNA profile of 
these white blood cells for diagnostic purposes.  Doing so requires a blood separation technique 
capable of producing a nearly pure white blood cell fraction.  As described below, an antibody-
based method will be implemented on the Diamond HemeSep Cartridge.  Antibodies are proteins 
produced by the white blood cells of the body’s immune 
system.  As shown in Figure 7.1, these antibodies contain 
sites that can bind their substrates, the antigens, much like a 
lock fits a key (18, 19).  The immunomagnetic separation 
system, therefore, is based on the extreme fidelity of 
antibody binding to their substrate molecules.  Selecting an 
antibody, chemically linked to a paramagnetic bead, that 
may bind exclusively to the white blood cells allows for the 
aggregation and subsequent collection of those white blood 
cells.  
 
Figure 7.1: Antibodies are proteins 
that bind their substrates, antigens, 
much like a key fits in a lock (36) 
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Immunomagnetic separation is quickly 
becoming a favored technique for efficiently 
isolating cells from bodily fluids (20).  The 
technique relies on the high affinity of 
antibodies, proteins produced by the immune 
system, for their target substrates.  The 
substrates are typically proteins bound to the 
membrane of a target cell.  As shown in Figure 7.2, when these antibodies are chemically 
conjugated to paramagnetic beads, they can be magnetically concentrated to the bottom of the 
well containing the whole blood along with their bound substrate, the white blood cells, 
facilitating separation of the bead-antibody-substrate from the remainder of the fluid. 
 
7.2 Leukocyte Common Antigen Antibody 
7.2.1 Justification for Separation 
 
The five types of white blood cells (neutrophils, basophils, eosinophils, monocytes and 
lymphocytes as discussed in Chapter 4) are responsible for all immunological functions and are 
the only nucleated cells in blood.  This means that they are the only blood cells containing DNA.  
As such, separation of these leukocytes is critical for hematological analyses and clinical 
diagnostic tests for studying progression of disease. 
Traditional methods for separating these cells take advantage of differences in buoyant 
gravity of the different blood components in a density gradient solution such as Ficoll-Paque™ 
or differences in average diameter between RBCs and WBCs using membrane technology.  
However, the former method requires careful attention of a human technician and therefore 
Figure 7.2: Antibodies chemically conjugated to 
paramagnetic beads facilitate isolation of substrate 
(white blood cells). 
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requires relatively large volumes of blood while the latter is prone to clogging.  Therefore, the 
use of immunomagnetic separation presents an interesting and perhaps more efficient, though 
slightly more costly method of WBC separation from the rest of the blood components. 
 
7.2.2 Background for Separation Antibody Design 
 
Immunomagnetic separation has several attractive features, including the high degree of 
specificity of antibody-substrate binding, the kinetics of antibody binding, and the ability to 
standardize a separation procedure using a liquid handling system. 
Antibody-substrate specificity refers to the fidelity of binding between the antibody and 
its substrate.  Ideally for separation purposes, an antibody will bind only to its substrate and not 
to other molecules, allowing for the most pure substrate to be obtained after magnetic 
concentration.   
 Antibodies generally bind quickly and specifically to their target substrates, making them 
ideal for use in a cartridge such as ours.  As shown in Figure 7.3, within about 5 minutes, more 
than 60% of antibodies can be expected to 
be bound to their targets after gentle mixing 
(21).  This provides for a quick, reliable and 
reproducible method for separating out 
white blood cells from whole blood without 
having to remove any of the other blood 
components first.  In our process, the total 
processing time for the white blood cells is 
Figure 7.3: Antibodies bind quickly and efficiently to 
their targets  after gentle mixing in a well with human 
whole blood (21) 
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around 13 minutes with only 5 minutes required for the antibodies to bind to the cells during an 
incubation step as discussed in Chapter 4. 
7.3 Magnetic Immunoprecipitation Design 
 
 In our chip, we utilize an antibody specific for leukocyte common antigen (LCA, also 
abbreviated as anti-CD45 antibody).  LCA is actually a family of trans-membrane glycoproteins 
expressed on the surface of all five types of white blood cells discussed in Chapter 4.  Five 
isoforms of LCA, named ABC, AB, BC, B and D have been identified and may be recognized by 
antibodies known as CD45RA, CD45RB, CD45RC and CD45RD.  Our cartridge will utilize a 
one of these antibodies to target all five isoforms of LCA. 
Because LCA is known to be expressed on all white blood cell types, it is an ideal choice 
for use in our separation, since antibodies specific to the various LCA isoforms may precipitate 
all types of white blood cells.  This simplifies the search for antibodies and increases the yield of 
white blood cells obtained from the separation.  Furthermore, established kits already exist for 
using such antibodies in separating white blood cells from whole blood. The kit used in the 
Diamond HemeSep cartridge is the DynaBeads FlowComp Human CD45RA isolation kit from 
Invitrogen, with a few modifications to the separation procedure as described in Chapter 4. 
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Chapter 8: Serum Separation via Microfiltration 
8.1 Introduction 
   
In order to create serum, filtration was the only logical solution.  While centrifugation is 
by far the most utilized technique, a micro-centrifuge in this setup would be impractical.  
Antibody techniques to pull down fibrin also would not work.  Antibodies selective for 
fibrinogen only remove fibrinogen while leaving all the other clotting factors in the plasma.  This 
produces defibrinated plasma instead of serum.  In addition, filters already exist to help keep 
serum separated from a clot when the sample is spun down in a centrifuge.  Thus, a filter system 
seems quite plausible.   
8.2 Physical Characteristics of Fibrin Clot 
 
The design of the filtration system depends on the characteristics of the fibrin clot.  
Because of the complexity of the reaction to form the clot, different species are present in the 
plasma at various times.  Luckily, the kinetics of this complex series of reactions has been 
studied extensively (7).  Multiple species are created in multiple reactions (Figure 8.1), the rates 
of which impact the 
overall structure and 
properties of the 
resulting clot.  As 
discussed in Chapter 5, 
protofibrils rapidly form 
after the introduction of 
thrombin.  These will 
Figure 8.1:  Normalized concentrations of various species against time 
Diamond HemeSep Blood Processing Unit  Moonan, Paranjape, Tirone, Wang 
 
80 
grow to an approximate length of 0.8µm and a weight of 3,500kDa (22).  These are consumed in 
the production of the much larger fibers that are characteristic of a clot.  These fibers grow to a 
diameter of around 0.2 µm and lengths on the scale of 100 µm.  Eventually, enough of these 
fibers are formed to create a gel.  If the filtration is timed correctly, it can take place when 
virtually all of the protofibril has been consumed in production of fiber, but before the onset of 
the gel.   
8.3 Membrane Selection 
 
With these characteristics in mind, a membrane had to be selected.  The efficiency of the 
filtration depends predominantly on the characteristics of the membrane.  The first challenge in 
selecting a membrane is determining the required pore size.  The pores of the membrane must be 
smaller than the particle in order to effectively reject it.  In addition, pores for linear 
proteins/particles must be smaller than those for globular proteins (23).  Most of the fibrin will 
be in the form of very large fibers or aggregated into a gel.  This suggests using a large pore size.  
However, some protofibril may remain.  As a result, a pore size of 1 µm was selected.  The use 
of membranes with this pore size for pre-filtration of serum before its use in easily clogged 
instruments validates this choice (24).   
With pore size selected, the membrane material was chosen.  This polymer must be 
hydrophilic, low-protein-binding and biologically inert.  A hydrophilic membrane is used to 
achieve desired wetting of the membrane by the aqueous solution.  In addition, hydrophilic 
membranes are less likely to adsorb serum proteins.  Although several polymers fit these criteria, 
we selected a 200 µm thick polysulfone membrane with a 1 µm pore size.  As the membrane by 
itself is only rated to 30psi, a porous polypropylene backing was selected for the membrane to 
increase rigidity.    
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8.4 Flow Rate Calculations 
 
The main difficulty in using filtration is the potential for the membrane to clog.  
However, the cartridge is single use, so the filter must work only once.  The membrane itself 
offers little resistance, but because fibrin is designed to prevent blood loss, it does an excellent 
job of impeding flow.  The gel that forms on the membrane is the major source of flow 
resistance.  Neglecting the resistance of the membrane, the flow through the fibrin gel can be 
modeled using Darcy’s law.   
                                                                  
 
 
  
 
                                                                   (8.1) 
Values of 2.5 g/L fibrinogen/L plasma, .001 Pa
.
s for the viscosity of fibrin and 0.2 g/mL for the 
density were used (25).  The height of the fibrin gel was calculated using the concentration of g 
fibrinogen/L in plasma and the fibrin density.  This height was used as the depth of the bed (L) in 
Darcy’s equation.  With a pressure of 50 psi, a flow rate of 59 μL/s was achieved.   
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Chapter 9: Microfluidic Design Principles 
9.1 Introduction 
 
 The design of microfluidic devices poses special challenges over their macro-scale 
counterparts.  Because the channel dimensions are no more than a few micrometers in size, 
highly precise fabrication techniques are needed.  Also, since the behavior of fluids is difficult to 
predict at these length scales, it is important to choose the channel material that offers the least 
amount of interaction between the working fluid.   A widely used microfabrication technique 
involves the use of photolithography and soft lithography in conjunction with 
polydimethylsiloxane (PDMS) and is an ideal fabrication technique when working with 
biological fluids. 
9.2 Photolithography 
 
 The process of photolithography involves the selective corrosion of a substrate into a 
desired design.  To achieve this, a photomask is designed in a computer-aided drawing (CAD) 
software package such as Solidworks, which is then laid on top of a silicon wafer coated with a 
light sensitive substrate (known as the “photoresist”)  (26).  There are two types of photoresists: 
positive and negative.  A positive photoresist, when exposed to UV light, will be corroded on 
portions that are covered by the photomask.  Alternatively, a negative photoresist will be 
corroded in areas that are not covered by the photomask (27).   Both processes can be seen in 
Figure 9.1 below.  
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Figure 9.1. Process of photolithography.  When exposed to UV light, positive resists are corroded in areas 
covered by the photomask and negative resists are corroded in areas not exposed by the photomask (27). 
Once the photoresist has been completely etched, the entire setup is “hard baked” to harden the 
photoresist and adhere it to the wafer surface. 
9.3 Soft lithography 
 
 To prepare the final microfluidic device, soft lithography must be used in conjunction 
with the “master” mold produced from the photolithography process.  Soft lithography involves 
the use of an elastomeric compound such as PDMS to produce the final design from the master 
mold via a series of curing steps.  First, PDMS is poured over the master mold, where it 
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solidifies when exposed to high temperatures.  The solid PDMS is then peeled off the master 
mold, resulting in the final microfluidic device (28).  This device is then fixed to a glass slide, 
creating the channels needed for the microfluidic device to work.  Figure 9.2 below shows the 
steps in the soft lithography process. 
 
Figure 9.2. Process of soft lithography.  Liquid PDMS is poured over the master mold, where it is exposed to 
high temperatures and cured into a solid.  The PDMS is then removed and is used as the final microfluidic 
device. Some common problems with the soft lithography process include pairing and sagging (28). 
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9.4 Polydimethylsiloxane 
 
 Polydimethylsiloxane (PDMS) is a silicon-based organic compound that is commonly 
used in microfluidic device designs.  It is optically clear, inert, non-toxic, and non-flammable.  It 
has the following chemical design: 
 
Figure 9.3: Structure of polydimethyl siloxane (PDMS) 
In Figure 9.3, n denotes the number of monomers in the compound.  The viscosity of PDMS can 
be increased by increasing the number of monomers (increasing n).  This can allow PDMS to 
take a liquid form (low n) or a rubbery semi-solid (high n)  (29).  This property makes it a 
particularly useful elastomer in soft lithography.  Other desirable properties of PDMS is that it 
does not swell with humidity (non-hydroscopic), it has high thermal stability, and it can be easily 
deformed and reshaped both mechanically and chemically  (28). 
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Chapter 10: Manufacturing Considerations 
10.1 Introduction 
 
 The Diamond HemeSep Cartridge will primarily be assembled from original equipment 
manufacturer (OEM) parts.  Such parts include the actual plastic cartridge containing the input 
and output wells, the reagents, and the actual liquid handling unit.  The microfluidic portion of 
the device will be manufactured in our own facilities, originally using manual labor in the 
prototyping phases and eventually moving towards an automated process with human operators.  
Originally, we proposed outsourcing microfluidic chip fabrication to an outside company, 
especially considering the sizeable cost associated with building a manufacturing facility.  
Ultimately, it seemed most sensible to protect the intellectual property of the cartridge by 
maintaining complete control over the chip’s fabrication. 
 As mentioned in the previous chapter, the microfluidic chip is composed of two layers, a 
PDMS layer and a glass layer (a glass slide).  The interface between these two layers is what 
creates the channels through which blood may flow.  To create the PDMS layer, soft 
photolithography replica molding, as described earlier, was decided upon for use.  
 While all of the other parts are to be obtained from OEMs, assembly still requires 
accurate and efficient delivery of reagents to the snap-in reagents section of the cartridge.  In 
order to accomplish our eventual goal of 100-200 cartridges per hour, we decided to use a 
robotic liquid handling system for delivering the reagents to their plastic wells.  A major 
consideration in assembly is storing the reagents at the required conditions. Calcium, stored as 
CaCl2 in TBS, may be stored indefinitely in solution at room temperature whereas thrombin must 
be stored dry at colder temperatures.  This means that the user must rehydrate the thrombin prior 
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to using the cartridge. This also necessitates delivery of the packaged cartridge on dry ice for 
preservation. 
 10.2 Fabrication of Microfluidic Device 
 
 The microfluidic chip will be composed of two layers including a glass slide and a PDMS 
layer.  PDMS was chosen because of its desirable properties in molding, its optical transparency 
to wavelengths as low as 300 nm, its good thermal and chemical stability and its low interfacial 
energy. 
 Soft photolithography was chosen as a method for fabrication of this PDMS portion of 
the device.  This process was chosen because it can yield a large number of devices with a high 
fidelity to the “master.”  Using a photosensitive resist, as described in Chapter 9, the PDMS layer 
will be patterned by exposure to UV light.  As described, this process begins with the creation of 
a master, which is fabricated by first creating a resist.   Spinning onto a silicon wafer creates this 
resist and the pattern is created via etching the imprint using UV irradiation.  Then, PDMS molds 
may be created from this master, which may be used on large numbers of chips.   Despite its 
positive features, PDMS has a few known negative attributes, including slight shrinking upon 
curing and difficulty in accurate patterning below about 10 μm scales.  Despite these few 
negatives, the utility and applicability of soft photolithography made it a desirable process for 
fabrication of our microfluidic chips. 
 To fit our goal of 100 – 200 microfluidic chips produced per hour, hundreds of molds 
will need to be produced for creation of the PDMS portions of the device.  For this, only a few 
masters will need to be created.  These masters will be created from normal lithography methods.  
The channels all have a height of 35 μm, lengths on the order of centimeters and widths ranging 
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from 15 to 60 μm.  These features are all within the size limits allowed by photolithography and 
can therefore be accurately fabricated using this technique. 
 In the fabrication process, as described earlier, master creation begins with the 
application of a positive photoresist onto a silicon wafer and spinning to get a resist thickness of 
35 μm.  Then, UV light is used to cross link areas not masked that correspond to the channels 
and reservoirs.  After this, the master is baked to cure unexposed resist and the exposed resist is 
washed with an organic developer that dissolves and etches these areas.  This causes the 
substrate to have channels 35 μm in depth and reservoirs in the positions indicated for our chip.   
This process is already diagramed in Figure 9.1 for negative photoresists. 
 After finishing the master, a negative PDMS mold to the final design pattern may be 
created (since a positive photoresist was used).  Hundreds of PDMS molds, containing many 
parallel master designs, will be created and used as a stamp.  Prior studies have shown that 
PDMS can be accurately used as a stamp after more than 10 uses (30).  This allows each stamp 
to have a lifetime of up to two months.  These parallel molds will be filled with PDMS and then 
thermally cured in a baking process that takes approximately two hours, giving desired PDMS 
devices with channels and reservoirs as needed to be sealed to the glass slide layer. 
 We have decided to outsource the creation of the masters while producing the molds and 
actual devices.  Each microfluidic device will require approximately 17.5 mL of PDMS.  This 
assumes less than 1% shrinkage.  To accomplish the production of 100-200 chips per hour, we 
Figure 10.1:  This figures displays the manufacturing process involved in creating PDMS chips. (1) A PDMS 
mold is created from a positive photoresist.  (2) This mold is filled with PDMS and cured in an oven at 80 C 
for 2 hours.  (3) the PDMS device is removed from the mold, which may be reused, and is then (4) adhered to 
a glass slide, creating the channels and reservoirs as indicated in the microfluidic chip design. 
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will begin each day by mixing PDMS with viscous curing agent in a 100 L tank containing 70 L 
of PDMS.  It will need to be mixed for 10 minutes.  Then, the mixture will be deposited onto the 
PDMS molds (blue in Figure 10.1) to create the microfluidic chip (gray in Figure 10.1).  The 
parallel molds will be placed in a curing oven for approximately two hours at 80 °C.  Based on 
the surface area of 4,000 PDMS molds, the oven needs to have a surface area of approximately 
60 ft
2
.  Based on a prior design project, by Abbot, Lee, Kohli and O’Brien, a suitable curing oven 
from Wisconsin Oven Corporation, priced at $22,400 may be used to accommodate the needs of 
the process. 
 While the devices cure, reagents are delivered to the plastic cartridge insert as described 
in the subsequent section.  Deposition of the antibody, Dyna-Beads, PBS, lysis buffer, thrombin 
and calcium will each require about 3 seconds for alignment and subsequent deposition of the 
liquid, amounting to a total of eighteen seconds.  The deposition of the reagents will take place in 
a cold environment to protect the reagents from degradation and evaporation. 
 Once the curing has completed, the PDMS chips are taken from the molds via a robotic 
arm and sealed to glass slides pre-coated with Sigmacote, a hydrophobic material, using a PDMS 
sealing machine which is estimated to cost $210,000.  From this unit, the chips will be shuttled to 
an assembly line where a robotic suction arm will assemble the reagent insert and microfluidic 
chip into the cartridge, then seal the cartridge and transport them into a freezer for delivery. 
 Our goal will be to produce approximately 100 – 200 cartridges per hour, corresponding 
to approximately 1 million cartridges per year. 
10.3 Robotic Liquid Handling System 
 
 Although most cartridge parts will be obtained from OEMs, reagents will still need to be 
delivered to the cartridge reagent insert prior to packaging.  To accomplish the delivery of 
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microliter volumes of reagent, a few different options were considered.  Namely, we considered 
the use of an inkjet handling system and a robotic pin tool.  While both of these technologies are 
capable of accurately and reproducibly delivering small quantities of liquid on the nanoliter 
scale, their use in microliter quantities is far too slow and costly to be of great use.  Instead, we 
opted to use a robotic liquid handling system.  This system is capable of delivering each reagent 
to the appropriate well in approximately 1-2 seconds, allowing us to realize our goal of 
manufacturing 100-200 cartridges per hour.  Since our design is based off of a standard 96 well-
plate micro-assay design, standard liquid handling robots sold may be used to insure accurate 
deposition of reagents.  This will work by passing the cartridge insert along a conveyer belt 
underneath the robotic liquid handling unit, where the unit may be programmed to deliver the 
reagents to the standard well plate locations.  Such a unit is estimated to cost $35,000 and is 
assumed to be able to deliver the reagents in 3 seconds per transfer. 
Because of the relatively large volumes (μl scale) of reagents being deposited into the 
wells, evaporation of reagents is of little concern.  According to the literature, approximately 1 nl 
of aqueous solution may be assumed to evaporate in approximately 30 seconds.  However, 
precautions to reduce the risk are to include more reagent than is necessary during cartridge 
operation and to seal the reagent wells with foil shortly following deposition.  This problem will 
be addressed as needed during the first year of testing. 
10.4 Manufacturing Schedule 
 
 Using an assumed market size of 1 million chips per year, which is roughly equivalent to 
the number of blood draws taken in clinical trials every year, and a market capture of 
approximately 50%, we will need to produce 500,000 chips per year. 
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 To meet this market capture goal, there are several considerations and assumptions to 
make.  First, we have assumed that the manufacturing facility can operate 8 hours a day, 5 days a 
week for 50 weeks of the year (250 total days).  Therefore, the number of chips needed for sale is 
given by equation 10.1: 
 
                      
                              
                              (10.1) 
 Furthermore, it is assumed that roughly 25% of chips manufactured will be used for 
quality control testing and therefore, an additional number of chips must be produced.  Of these 
chips, it is assumed 25% of them will be defective, such that the requisite number of chips is 
given by equation 10.2: 
       
                   
       
                          (10.2) 
 This schedule assumes manufacturing starts at time t = 0 (9:00 AM).  Mixing and 
deposition of PDMS onto the molds is represented by the box labeled “mix/dep”.  Mixing takes 
approximately 10 minutes and each deposition is assumed to take 3 seconds.  It is assumed that 
10 chips’ worth of PDMS can be deposited to the molds per deposition yielding the following 
amount of time necessary for the step: 
 
                                   
                       
           (10.3) 
 The chips are then cured in an oven for a total time of 2 hours.  Simultaneously, the 
reagents are deposited into the cartridge using the times discussed above: 
 
         
       
 
          
    
 
          
   
             (10.4) 
 Because this time exceeds the typical work day, two liquid handling robots will be run in 
parallel for a total of 7 hours each.  Note that these calculations are for the final year of 
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production, and that manufacturing facilities can be modified as necessary during actual 
production. 
 After removing the PDMS layers from the oven, they need to be sealed to the glass layer 
to complete the microfluidic device.  This process is estimated to take 8 hours (4 hours if split 
into two batches) and may begin as soon as the PDMS layers are removed from the oven (i.e., 
simultaneously with reagent loading).  Doing so saves time during the process. 
 Subsequently, the cartridge needs to be assembled and packed.  This process is estimated 
to take roughly 4 hours (for two batches) and may begin midway through the reagent deposition 
as inserts become available to be assembled into cartridges.  Doing so allows the cartridges to be 
assembled over the course of a typical workday as displayed in Figure 10.2 below.
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Figure 10.2: Scheduling for the manufacturing process 
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Chapter 11: Diamond HemeSep Development Timeline 
 
11.1 Introduction 
 
 After completing the design stage, we project that the Diamond HemeSep cartridge can 
be marketed for use within a year.  This time is primarily required for acquiring FDA approval 
for the device, although part of the time will be simultaneously used for research and 
development to improve on design weaknesses discussed in the report. 
11.2 Product Development and Prototyping 
 
 We have allocated one year for seeking FDA approval and further optimization of the 
cartridge system.  Preliminary experimental results showed that the device can successfully skim 
plasma from whole blood, but further tuning is required.  During this time period, scientists and 
engineers will need to address a few key issues to insure the success of the project.  Specifically, 
experimental results suggested that the channel dimensions chosen can handle flow rates as high 
as 25 µL/min as opposed to the 10.5 µL/min assumed previously. 
  
11.3 FDA Approval 
 
 The Diamond HemeSep Cartridge is considered to be a medical device, necessitating that 
FDA approval be obtained before the product may begin to be distributed to hospitals and 
clinical research facilities.  As is the case with obtaining FDA approval for any such device, we 
must first classify what class the device falls into.  Class I devices include basic medical 
instruments whose proper functioning can be determined from inspection and whose failure 
poses no harm to the patient.  Class III devices are devices whose failure could pose significant 
or life threatening harm to the patient.  An example of a Class I device includes band-aids 
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whereas a Class III device would be something like a pacemaker.  The Diamond HemeSep 
cartridge seems to fall in the middle of these two extremes under Class II (31).  The device has a 
potential to fail so its safety and efficacy must be substantiated.  However, failure of the device 
poses no direct threat to the patient.  To verify this product classification, product design 
specifications, manufacturing protocols and prototypes must be sent to the FDA.  After obtaining 
this verification, the appropriate paperwork can be filed and clinical trials can commence. 
11.3.1 Clinical Trials 
 
 In acquiring FDA approval for the device, it will need to be proved that the Diamond 
HemeSep Cartridge is both safe and effective.  To this end, it may be most beneficial to try and 
prove Substantial Equivalence.  According to the FDA, proving substantial equivalence means 
that, in comparison to a predicate product, the new product: has the same intended use and 
different technological characteristics than the predicate, but that do not raise new questions of 
safety and effectiveness. 
 The safety and effectiveness of the Diamond HemeSep Cartridge will be verified through 
a series of clinical trials.  Test subjects in each Phase of the trials will have multiple blood 
samples collected, some of which will be analyzed using conventional centrifugation and the 
remainder of which will be processed using the Diamond HemeSep.  The former samples will 
serve as controls against the latter. 
11.3.2 Phase I 
 
 Phase I is estimated to take 1 month to run and analyze.  Its main purpose will be prove 
that the Diamond HemeSep cartridge is safe and does not show a variance in blood plasma 
purity, serum purity or DNA profile obtained from blood processing when compared to 
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conventional laboratory methods such as centrifugation.  To this end, 75 test subjects will be 
used.  Each subject will have two 5 mL blood samples drawn and tested using both 
centrifugation and the Diamond HemeSep.  Then, the obtained blood fractions will be examined 
using a smear technique for determining plasma and serum purity and the DNA profiles obtained 
from the WBC samples will be compared using the centrifuged sample as a control. 
11.3.3 Phase II 
 
 Phase II will take approximately 5 months to complete and will primarily serve to prove 
the efficacy of the device as well as continued safety.  To do so, the number of test subjects will 
be increased to approximately 300 with each subject being tested three times at one week 
intervals as described before.  The blood will be tested as in phase I and the results will be 
compiled and analyzed for variation in the results due to the different separation methods. 
11.3.4 Phase III 
 
 Phase III has an estimated duration of 6 months.  Its purpose is to prove that the device is 
ready for distribution and use in clinical research facilities.  In this trial, the number of subjects 
will increase to approximately 3000 with each subject being tested exactly as before but for a 
total of four times at one week intervals.  As before, the data will be compiled and analyzed. 
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11.4 Preparation for Manufacturing 
 
 After successful results have been obtained from the clinical trial series and while waiting 
for FDA approval, manufacturing facilities will be set up.  Production space will be leased and 
the parts obtained from OEMs will be assembled into Diamond HemeSep Cartridges once FDA 
clearance has been received. 
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Chapter 12: Financial Analysis 
12.1 Market Projection 
 
 We have projected the company’s expected revenues over a reasonable time horizon of 
10 years and also assumed a product life of 10 years for our base case analysis. Research and 
development will commence in 2013 and production will begin in 2014. From consulting with 
industry professionals at Becton Dickinson, a reasonable base case price for the cartridge and the 
processing unit are $25 and $100,000, respectively.  An inflation rate of 2.5% was assumed. This 
was based on average annual inflation rate of 2.5% from 2002 to 2012 (32). We have assumed 
that the Diamond HemeSep will reach a market share of 50% by the third year of production and 
that this share will be maintained for subsequent production years.  
 Table 12.1 shows total annual revenues. Complete market projections calculations can be 
found in Appendix 16.5.1. 
End of 
Year Total Revenues 
2013 $0 
2014 $20,275,781 
2015 $46,284,540 
2016 $84,295,269 
2017 $30,141,247 
2018 $22,872,920 
2019 $24,734,204 
2020 $26,746,950 
2021 $28,923,483 
2022 $31,277,131 
2023 $33,822,308 
Table 12.1 Total revenues with base case assumptions 
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12.2 Costs Sheet 
 
 The costs of reagents have been confirmed with sales representatives from suppliers and 
a 25% discount was applied to take into account of bulk purchasing prices. Per Dr. Diamond and 
consultants, the costs of the microfluidic chip, micro-filter, and magnet are estimated as $5 per 
chip, $1 per well, and $100 per well, respectively.  
 Costs of manufacturing the liquid handler from OEM’s have been estimated as $11,500. 
This figure was estimated from considering a price quote of $75,000 from sales representatives 
of Becton-Coulter and assuming an 85% mark-up. This estimate lies within the ball-park of 
estimates from Dr. Diamond and industry consultants.  
 Costs of manufacturing machinery and equipment are estimated in Chapter 10.  
 Laboratory and corporate space costs were estimated at $10/ft
2
/month and manufacturing 
space costs were estimated at $8/ft
2
/month. Salaries were based on estimates by the design team 
(2, 4-6, 32, 33).  
 Clinical trials are estimated at $2.5 MM for material and human costs. FDA approval, 
including application and legal fees is estimated to cost approximately $500,000 (2, 4-6, 32, 33).  
 R&D start-up costs are a lump-sum to cover materials, utilities, extra equipment, and 
anything else our scientists might need. These costs are assumed to be approximate $1 MM per 
year pre-production. Once production has begun, 5% of revenues will be re-invested in R&D so 
that product offerings can be improved and expanded. Lab information management software 
cost was assumed to be $100,000 (2, 4-6, 32, 33).  
 Cost estimations are detailed in Appendix 16.5.2. 
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12.3 Operating Assumptions 
 
 Sales, General, and Administrative costs (SG&A), also known as overhead, are assumed 
to be a percentage of revenues. Due to a learning curve, overhead functions are expected to 
become more efficient over time, so SG&A costs are expected to reduce in subsequent years.  
 Estimates of laboratory space were based on 250 sq. ft/person. Estimates for corporate 
space were based on 100 sq. ft. per person in management and 75 sq. ft. per person for all other 
employees. The number of employees required is based on the design team’s best estimates for 
equipment operation and company growth (2, 4-6, 32, 33).  
 The number of pieces for each process machine is based on manufacturing considerations 
and is justified in Chapter 10. Operating assumptions are detailed in Appendix 16.5.3. 
12.4 Inventory, Working Capital, and PP&E 
 
 Inventory was found by summing the total cost of the cartridges and the processing units 
needed for that particular year. Since all costs were given in 2012 dollars, adjustments for 
inflation were made.  
 Working capital is found by subtracting current liabilities from current assets. Current 
assets are calculated by the sum of accounts receivable and inventory. Accounts receivable is 
based on the outstanding amount owed to the company by customers that have not yet paid for 
products that is calculated by multiplying total revenues by 1/12, or 8.33%, which is thirty days 
out of the year. Inventory is typically held for seven days. To find the working capital cost of 
holding on to this inventory, total revenues in a particular year are multiplied by 1.92%, which is 
seven days out of the year. Current liabilities consist of accounts payable and cash reserves for 
salaries. Accounts payable is the outstanding amount that a company owes to a supplier for 
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goods that have been delivered. Accounts payable is calculated by multiplying the cost of 
inventory, depreciation, maintenance capital expense (capex), and overhead by 8.33%, which 
accounts for thirty days to pay suppliers. Cash reserves for salaries are the amount of cash 
needed to pay all employees for one month. Additional working capital for year n is found by 
subtracting the working capital for year n-1 from the working capital needed for year n. This 
represents a change in free cash flow and can be found as a line item in the free cash flow 
section.   
 Net Plant, Property, and Equipment expenses were calculated by summing the beginning 
account, purchases, and maintenance capex and subtracting the accumulated appreciation. Since 
the Diamond HemeSep is leasing laboratory, production, and corporate space, these costs are not 
included in PP&E. Equipment purchases are the cost of all equipment purchased in a given year. 
Maintenance capex consists of equipment needed to maintain previously purchased equipment 
and machinery. Maintenance capex was estimated to be 10% of the total cost of equipment from 
previous years.  
 Depreciation was found using the MARCS depreciation schedule. The Diamond 
HemeSep’s equipment falls into a class life of 10 years. The basis for depreciation was found by 
summing the equipment purchases and the maintenance capex for the respective year.   
 The breakdown of inventory, working capital, and PP&E are detailed in Appendix 16.5.4. 
12.5 Income Statement 
 
 The income statement shows how the Diamond HemeSep’s revenues are transformed 
into net income. Cost of goods sold (COGS), which are the direct costs attributable to the 
production of goods, are subtracted from Revenues to arrive at gross profit. Next, indirect 
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expenses are subtracted from gross profit to arrive at earnings-before-interests-and-taxes (EBIT). 
To find net income, a typical 37% tax rate was assumed. If the EBIT is negative, a tax benefit 
can be applied often referred to as a deferred tax asset. The negative earnings are not taxed, but 
instead they are carried forward and deducted from positive taxable income in the future. 
Assuming Diamond HemeSep has no debt, taxes are subtracted from EBIT to arrive at Net 
Income. Appendix 16.5.5 provides a thorough breakdown of the income statement. 
End of Year Gross Profit % Margin EBIT % Margin  Net Income % Margin  
2013  $                     -  0%  $ (5,048,125) 0% ($5,048,125) 0% 
2014  $  15,838,316  78%  $ 10,826,102  53% $8,688,250  43% 
2015  $  36,687,412  79%  $ 29,173,940  63% $18,379,582  40% 
2016  $  66,998,446  79%  $ 55,824,601  66%  $  35,169,499  42% 
2017  $  18,976,395  63%  $ 12,281,591  41%  $    7,737,402  26% 
2018  $  10,799,528  47%  $   4,795,796  21%  $    3,021,351  13% 
2019  $  11,678,340  47%  $   5,377,751  22%  $    3,387,983  14% 
2020  $  12,628,665  47%  $   6,040,052  23%  $    3,805,233  14% 
2021  $  13,656,322  47%  $   6,810,615  24%  $    4,290,687  15% 
2022  $  14,767,605  47%  $   7,656,240  24%  $    4,823,431  15% 
2023  $  15,969,319  47%  $   8,573,781  25%  $    5,401,482  16% 
Table 12.2: Net income statement for the Diamond HemeSep blood processing unit. 
12.6 Free Cash Flow 
 
 Free cash flow represents the cash that a company is able to generate after the expenses 
required to maintain or expand its asset base has been paid. Free cash flow is a basis to determine 
the valuation of a company using the Discounted Cash Flow method. It is calculated as operating 
cash flow minus capital expenditures. Operating cash flow is net income plus adjustments for 
non-cash items such as depreciation and working capital. Capital expenditures are assumed to be 
purchases of PP&E (2, 4-6, 32-34). The free cash flow generated each year are shown in 
Appendix 16.5.6. 
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12.7 Valuation and Returns 
 
 The value of the Diamond HemeSep is determined by the Discounted Cash Flow method. 
Free cash flow was projected over the ten year horizon. A terminal value was determined at the 
end of year ten by using the perpetuity formula and assuming a conservative growth rate of zero. 
The free cash flows for each year and the terminal value are then discounted to present value 
using a discount rate.  
 The discount rate was determined using the Capital Asset Pricing Model (CAPM) and 
assuming that the ownership of Diamond HemeSep is 100% equity based. Risk free rate was 
estimated using 10 year Treasury bill rate. A typical market risk premium of 7% was assumed. 
Since the Diamond HemeSep is a novel medical device, a relatively risky venture, a typical beta 
for this industry of 2 was assumed. Using CAPM, the equity discount rate is 16%.  
                       
We calculated the Internal Rate of Return (IRR) for investors. A company usually goes 
through multiple rounds of financing. Since Diamond HemeSep is a product-focused venture 
with relatively fast go-to-market time, we have considered one round of financing to estimate 
IRR. Series A financing is the first round of financing undergone for a new business venture and 
is typically the first time that company ownership is offered to external investors, such as venture 
capital and angel investors. Financing is assumed to be provided in the form of convertible 
preferred stock (2, 4-6, 32-35).  
 The NPV of Diamond HemeSep is approximately $51MM and its IRR is approximately 
45%. The IRR is greater than the discount rate and falls within investor’s preference of 30%-
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50% IRR for risky companies. Table 12.3 provides a summary of assumptions and results of the 
valuation analysis. A thorough breakdown of the valuation analysis is shown in Appendix 16.5.7. 
 
  
 
 
 
 
 
 
12.8 Payback period 
 
 The payback period is the length of time required to recover the cost of an investment. 
Usually, the goal of a start-up company is to achieve payback period of two years after 
production (2, 4-6, 32-35).  
 Two methods of calculating the payback period can be used – simple or discounted. The 
simple payback period ignores the time value of money, whereas the discounted payback period 
takes into account the time value of money. Cumulative present wealth (PW) is calculated from 
summing the free cash flows. The payback period occurs when the cumulative PW goes from 
negative to positive. While the discounted method is used more often, some analysts still like to 
see both methods.  
 For the Diamond HemeSep, the payback period under the simple and the discounted 
methods are one and two years respectively after production has begun. Appendix 16.5.8 
provides further details on the calculation behind the payback period.  
Perp. Growth rate 0.00% 
Risk Free Rate (10 year treasury 
bill) 
2.23% 
Market Risk Premium 7.00% 
Beta 2 
Discount Rate 16.23% 
  
NPV $50,601,988 
IRR to Series A Investor 45% 
Table 12.3: NPV and IRR for a Series A investor of 
the Diamond HemeSep blood processing unit. 
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12.9 Sensitivity Analysis 
 
 Sensitivity analysis was performed to study how NPV and IRR fluctuated with respect to 
the following variables: market share, price, and number of clinical trial years. For each variable, 
worst and best case scenarios were considered.  
12.9.1 Sensitivity to Market Share 
 
 The base case assumes market share of 15%, 30%, 50% in first three years of production 
and market share saturation at 50%. While this assumption is ambitious, we believe that the 
Diamond HemeSep is a novel technology that is capable of disrupting the market, has little 
competition, and could become an industry standard. However, these values may change 
depending on other factors such as later entrants by competitors and sensitivity analysis was 
performed to determine the impact on NPV and IRR of the company. Our analysis shows that the 
NPV and IRR are quite sensitive to market share. Under the worst case scenario, if the Diamond 
HemeSep only achieves a market penetration rate of 25%, the NPV will be $12MM and the IRR 
will be 20%. The company would still be profitable, but the investment is certainly not as 
attractive. On the other hand, our analysis also shows that the Diamond HemeSep has the 
potential to increase value through increased market share. Under the best case scenario, if the 
Diamond HemeSep continues to grow its market share at 5% growth rate after 50% penetration, 
the NPV will be approximately $69MM and the IRR will be 51%. This analysis demonstrates the 
importance of market share. Thus, Diamond HemeSep should try to leverage its first-mover 
advantages and aggressively solidify market share early on.  
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% Change in Market Share from Base Year 
  NPV % Change 
IRR to 
Series A 
% 
Change 
Worst Case         
0,5,10,15,20,25,25,25,25,25 $11,858,888 -77% 20% -55% 
0,10,20,30,30,30,30,30,30,30 $24,845,293 -51% 32% -29% 
Base Case         
0,15,30,50,50,50,50,50,50,50 $50,601,988 0% 45% 0% 
Best Case         
0,15,30,50, grows at 3% $60,630,408 20% 48% 8% 
0,15,30,50,grows at 5% $68,526,272 35% 51% 14% 
Table 12.4: Sensitivity to Market Share for the Diamond HemeSep blood processing unit 
12.9.2 Sensitivity to Price 
 
 The base case assumes that the cartridge will sell for $25 and $100K for the processing 
unit. These prices can vary due to competition and other market dynamics. Our sensitivity 
analysis shows that the NPV and IRR still fall within reasonable and attractive values in worst 
case scenarios. 
  NPV % Change 
IRR to 
Series A 
% 
Change 
Worst Case         
-20% change in price $28,052,057 -45% 34% -24% 
-10% change in price $39,327,023 -22% 40% -11% 
Base Case         
0% change in price $50,601,988 0% 45% 0% 
Best Case         
+10% change in price $61,876,954 22% 49% 9% 
+20% change in price $73,151,919 45% 52% 17% 
Table 12.5: Sensitivity to Price for the Diamon HemeSep blood processing unit. 
12.9.3 Sensitivity to Number of Clinical Trial Years 
 
 Under base case assumptions, the Diamond HemeSep will undergo one year of clinical 
trials. The actual amount of time required for clinical trials and FDA approvals could vary due to 
delays and setbacks. Since the Diamond HemeSep falls under Class II Medical Device category, 
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it has a relatively short clinical trial period. In worst case scenario, the Diamond HemeSep might 
undergo one additional year of clinical trials, which will result in an NPV of $34MM and IRR of 
37%.  
  NPV % Change 
IRR to 
Series A 
% 
Change 
Base Case         
1 year $50,601,988   45%   
Worst Case         
2 years $34,371,999 -32% 37% -16% 
Table 12.6: Sensitivity to an additional clinical trial year for the Diamond HemeSep blood processing unit 
 
12.10 Summary 
 Overall, the Diamond HemeSep is expected to be a profitable venture. Under base case 
assumptions, the Diamond HemeSep can generate a positive NPV of $50MM and investors can 
expect an approximate IRR of 45%. The Diamond HemeSep’s payback period is short and 
expected to be within one or two years after production. These metrics suggest that the Diamond 
HemeSep is a highly attractive investment.  
 Our sensitivity analysis revealed that the Diamond HemeSep’s NPV and IRR are quite 
sensitive to market share. Our base case assumption that the Diamond HemeSep will achieve 
market penetration of 50% after 3 years of production is ambitious, but justified from our 
analysis of the market dynamics. Thus, the Diamond HemeSep should take full-advantage of its 
first-mover position and secure as much market share early on as possible.  
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Chapter 13: Recommendations and Conclusions 
 
 The realization of the Diamond HemeSep cartridge system promises to revolutionize the 
healthcare industry and provide researchers and physicians with a powerful and efficient 
diagnostic tool.  However, the design proposed in this report will require adaptations and 
enhancements if it is to reach its full potential. 
 Although our microfluidic design achieved positive results in the lab, modifications must 
be made to the device geometry to increase its plasma separation efficiency.  Specifically, the 
flow rate resistance ratios will need to be increased by either elongating the microfluidic 
channels or providing additional micro-valves to increase the pressure drops across the daughter 
channel.  Another largely unproven component of the Diamond HemeSep cartridge is our serum 
separation apparatus.  Although the laws that govern the filtration process are well known, the 
physical behavior of the device cannot be predicted with complete accuracy and will require 
laboratory testing before it can be confidently implemented in the cartridge.  These modifications 
and testing would be expected to occur during the yearlong research and development stage of 
our manufacturing process. 
 Further study will also need to be focused on proving the efficacy of the Diamond 
HemSep cartridge compared to traditional centrifugation processes.  Specifically, the 
composition and purity of the cartridge outputs must be on par with existing technology and the 
reproducibility of the cartridge outputs must be demonstrated as well. 
 Although our market and economic analysis focuses solely on the research and 
development segment, clinical uses of the Diamond HemSep cartridge system can be expected as 
well.  For instance, it has been found that fatal inflammatory responses can occur in 
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postoperative patients that undergo procedures involving cardiopulmonary bypass.  These 
responses include the secretion of pro-inflammatory cytokines into the blood stream along with 
other measurable blood changes.  By implementing the Diamond HemeSep system in hospitals, 
patients’ blood can be analyzed in real-time during the procedure to quickly respond to and treat 
this inflammatory response. 
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Chapter 16: APPENDIX 
16.1 MSDS Reports 
16.1.1 PDMS 
Material Safety Data Sheet 
Poly(dimethylsiloxane) 
ACC# 95130  
Section 1 - Chemical Product and Company Identification 
MSDS Name: Poly(dimethylsiloxane)  
Catalog Numbers: AC178440000, AC178442500, AC178445000  
Synonyms: Simethicone; Dimethicone.  
Company Identification: 
              Acros Organics N.V. 
              One Reagent Lane 
              Fair Lawn, NJ 07410 
For information in North America, call: 800-ACROS-01 
For emergencies in the US, call CHEMTREC: 800-424-9300 
Section 2 - Composition, Information on Ingredients  
 
CAS# Chemical Name Percent EINECS/ELINCS 
9016-00-6 Poly(dimethylsiloxane) 100  unlisted  
 
Section 3 - Hazards Identification  
 
EMERGENCY OVERVIEW 
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Appearance: clear liquid. 
Caution! May cause eye, skin, and respiratory tract irritation. The toxicological properties of this 
material have not been fully investigated.  
Target Organs: None known.  
 
 
Potential Health Effects  
Eye: May cause eye irritation.  
Skin: May cause skin irritation. May be harmful if absorbed through the skin.  
Ingestion: May cause irritation of the digestive tract. May be harmful if swallowed.  
Inhalation: May cause respiratory tract irritation. May be harmful if inhaled.  
Chronic: Adverse reproductive effects have been reported in animals. Animal studies have 
reported the development of tumors.  
Section 4 - First Aid Measures  
 
 
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting 
the upper and lower eyelids. If irritation develo ps, get medical aid.  
Skin: Immediately flush skin with plenty of water for at least 15 minutes while removing 
contaminated clothing and shoes. Get medical aid if irritation develops or persists.  
Ingestion: Do not induce vomiting. Get medical aid if irritation or symptoms occur.  
Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give 
artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough or other 
symptoms appear.  
Notes to Physician: Treat symptomatically and supportively.  
Section 5 - Fire Fighting Measures  
 
 
General Information: As in any fire, wear a self-contained breathing apparatus in pressure-
demand, MSHA/NIOSH (approved or equivalent), and full protective gear.  
Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or appropriate foam.  
Flash Point: > 100 deg C (> 212.00 deg F)  
Autoignition Temperature: Not applicable.  
Explosion Limits, Lower:Not available.  
Upper: Not available.  
NFPA Rating: (estimated) Health: 1; Flammability: 1; Instability: 0  
Section 6 - Accidental Release Measures  
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General Information: Use proper personal protective equipment as indicated in Section 8.  
Spills/Leaks: Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in 
suitable container. Provide ventilation. Do not let this chemical enter the environment.  
Section 7 - Handling and Storage  
 
 
Handling: Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid 
ingestion and inhalation.  
Storage: Store in a cool, dry place. Store in a tightly closed container.  
Section 8 - Exposure Controls, Personal Protection  
 
 
Engineering Controls: Facilities storing or utilizing this material should be equipped with an 
eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations 
low.  
Exposure Limits  
Chemical Name ACGIH NIOSH OSHA - Final PELs 
Poly(dimethylsiloxane)  none listed  none listed  none listed  
 
OSHA Vacated PELs: Poly(dimethylsiloxane): No OSHA Vacated PELs are listed for this 
chemical.  
Personal Protective Equipment  
Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by 
OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.  
Skin: Wear appropriate protective gloves to prevent skin exposure.  
Clothing: Wear appropriate protective clothing to prevent skin exposure.  
Respirators: A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI 
Z88.2 requirements or European Standard EN 149 must be followed whenever workplace 
conditions warrant respirator use.  
Section 9 - Physical and Chemical Properties  
Diamond HemeSep Blood Processing Unit  Moonan, Paranjape, Tirone, Wang 
 
117 
 
 
Physical State: Liquid  
Appearance: clear  
Odor: odorless  
pH: Not available.  
Vapor Pressure: Not available.  
Vapor Density: Not available.  
Evaporation Rate:Not available.  
Viscosity: 100 cSt @ 25 deg C  
Boiling Point: > 65 deg C @ 760 mmHg  
Freezing/Melting Point:Not available.  
Decomposition Temperature:Not available.  
Solubility: Insoluble.  
Specific Gravity/Density:0.965  
Molecular Formula:Not available.  
Molecular Weight:Not available.  
Section 10 - Stability and Reactivity  
 
 
Chemical Stability: Stable under normal temperatures and pressures.  
Conditions to Avoid: Incompatible materials, excess heat.  
Incompatibilities with Other Materials: Strong oxidizing agents, strong acids, strong bases.  
Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, silicon dioxide.  
Hazardous Polymerization: Will not occur.  
Section 11 - Toxicological Information  
 
 
RTECS#:       
CAS# 9016-00-6: TQ2690000  
LD50/LC50: 
Not available. 
 
Carcinogenicity: 
CAS# 9016-00-6: Not listed by ACGIH, IARC, NTP, or CA Prop 65. 
 
Epidemiology: Tumorigenic effects have been reported in experimental animals.  
Teratogenicity: No information found  
Reproductive Effects: Adverse reproductive effects have occurred in experimental animals.  
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Mutagenicity: No information found  
Neurotoxicity: No information found  
Other Studies:  
Section 12 - Ecological Information  
 
 
Ecotoxicity: Fish: Rainbow trout: LC50 > 10000 mg/L; 96 Hr; UnspecifiedFish: 
Bluegill/Sunfish: LC50 > 10000 mg/L; 96 Hr; Static bioassay Based on the Koc values, this 
substance will be immobile in soil and is expected to adsorb to particulates and organic matter in 
the water column. Rapid and extensive degradation is expected on dry surface soils. Some 
microbial degradation of small compounds is likely. High molecular weight 
poly(dimethylsiloxane) may bioconcentrate in aquatic organisms.  
Environmental: Poly(dimethylsiloxane) with lower molecular weights exist in the atmosphere 
in the vapor and particulate phases. Those with higher molecular weights exist solely in the 
particulate phase. Particulate phase poly(dimethylsiloxane) will be removed from the atmosphere 
by dry deposition while vapor phase poly(dimethylsiloxane) will be degraded by the reaction 
with photochemically-produced hydroxyl radicals with a half-life of 32 hours.  
Physical: No information available.  
Other: Do not empty into drains.  
Section 13 - Disposal Considerations  
 
Chemical waste generators must determine whether a discarded chemical is classified as a 
hazardous waste. US EPA guidelines for the classification determination are listed in 40 CFR 
Parts 261.3. Additionally, waste generators must consult state and local hazardous waste 
regulations to ensure complete and accurate classification.  
RCRA P-Series: None listed.  
RCRA U-Series: None listed.  
Section 14 - Transport Information  
 
 
US DOT Canada TDG 
Shipping Name: Not regulated. Not regulated. 
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Hazard Class: 
  
UN Number: 
  
Packing Group: 
  
 
Section 15 - Regulatory Information  
 
US FEDERAL 
 
TSCA  
     CAS# 9016-00-6 is not listed on the TSCA inventory. It is for research and development use 
only.  
Health & Safety Reporting List 
     None of the chemicals are on the Health & Safety Reporting List.  
Chemical Test Rules 
     None of the chemicals in this product are under a Chemical Test Rule.  
Section 12b 
     None of the chemicals are listed under TSCA Section 12b.  
TSCA Significant New Use Rule 
     None of the chemicals in this material have a SNUR under TSCA.  
CERCLA Hazardous Substances and corresponding RQs 
     None of the chemicals in this material have an RQ.  
SARA Section 302 Extremely Hazardous Substances 
     None of the chemicals in this product have a TPQ.  
Section 313      No chemicals are reportable under Section 313.  
Clean Air Act: 
     This material does not contain any hazardous air pollutants.  
     This material does not contain any Class 1 Ozone depletors.  
     This material does not contain any Class 2 Ozone depletors.  
Clean Water Act: 
     None of the chemicals in this product are listed as Hazardous Substances under the CWA.  
     None of the chemicals in this product are listed as Priority Pollutants under the CWA.  
     None of the chemicals in this product are listed as Toxic Pollutants under the CWA.  
OSHA: 
     None of the chemicals in this product are considered highly hazardous by OSHA.  
STATE 
     CAS# 9016-00-6 is not present on state lists from CA, PA, MN, MA, FL, or NJ.  
 
California Prop 65 
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California No Significant Risk Level: None of the chemicals in this product are listed.  
 
European/International Regulations 
European Labeling in Accordance with EC Directives 
Hazard Symbols: 
      Not available.  
Risk Phrases: 
 
Safety Phrases: 
     S 24/25 Avoid contact with skin and eyes.  
 
WGK (Water Danger/Protection) 
     CAS# 9016-00-6: No information available.  
Canada - DSL/NDSL 
     CAS# 9016-00-6 is listed on Canada's DSL List.  
Canada - WHMIS 
     This product has a WHMIS classification of D2B.  
This product has been classified in accordance with the hazard criteria of the Controlled Products 
Regulations and the MSDS contains all of the information required by those regulations.  
Canadian Ingredient Disclosure List 
Section 16 - Additional Information  
 
MSDS Creation Date: 5/14/1999  
Revision #4 Date: 1/11/2008  
 
The information above is believed to be accurate and represents the best information currently 
available to us. However, we make no warranty of merchantability or any other warranty, 
express or implied, with respect to such information, and we assume no liability resulting from 
its use. Users should make their own investigations to determine the suitability of the information 
for their particular purposes. In no event shall Fisher be liable for any claims, losses, or 
damages of any third party or for lost profits or any special, indirect, incidental, consequential 
or exemplary damages, howsoever arising, even if Fisher has been advised of the possibility of 
such damages.  
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16.1.2 Thrombin 
 
Diamond HemeSep Blood Processing Unit  Moonan, Paranjape, Tirone, Wang 
 
122 
 
Diamond HemeSep Blood Processing Unit  Moonan, Paranjape, Tirone, Wang 
 
123 
16.1.3 Calcium Chloride 
Material Safety Data Sheet 
Calcium Chloride, Anhydrous, 95%, Irregular Granules 
ACC# 95782  
Section 1 - Chemical Product and Company Identification 
MSDS Name: Calcium Chloride, Anhydrous, 95%, Irregular Granules  
Catalog Numbers: AC219170010, AC219170025, AC219170250, AC219175000, 
AC300380000, AC300380010 AC300380010, AC300380025, AC300382500  
Synonyms: Calpus; Caltac; Dowflake; Liquidow; Peladow; Snowmelt; Superflake Anhydrous.  
Company Identification: 
              Acros Organics N.V. 
              One Reagent Lane 
              Fair Lawn, NJ 07410 
For information in North America, call: 800-ACROS-01 
For emergencies in the US, call CHEMTREC: 800-424-9300 
Section 2 - Composition, Information on Ingredients  
 
CAS# Chemical Name Percent EINECS/ELINCS 
10043-52-4 Calcium chloride 95%  233-140-8 
 
Hazard Symbols: XI  
Risk Phrases: 36  
Section 3 - Hazards Identification  
 
EMERGENCY OVERVIEW 
Appearance: white solid. May be harmful if swallowed. May cause severe respiratory and 
digestive tract irritation with possible burns. May cause severe eye and skin irritation with 
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possible burns. May cause cardiac disturbances. Hygroscopic (absorbs moisture from the air). 
Warning!  
Target Organs: Heart.  
 
 
Potential Health Effects  
Eye: Contact with eyes may cause severe irritation, and possible eye burns.  
Skin: Contact with skin causes irritation and possible burns, especially if the skin is wet or 
moist.  
Ingestion: May cause severe gastrointestinal tract irritation with nausea, vomiting and possible 
burns. May cause cardiac disturbances. May be harmful if swallowed. In very severe cases, 
seizures, rapid respiration, slow heartbeat, or death, may result.  
Inhalation: May cause severe irritation of the upper respiratory tract with pain, burns, and 
inflammation.  
Chronic: Effects may be delayed.  
Section 4 - First Aid Measures  
 
 
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting 
the upper and lower eyelids. Get medical aid.  
Skin: Get medical aid. Immediately flush skin with plenty of water for at least 15 minutes while 
removing contaminated clothing and shoes. Wash clothing before reuse.  
Ingestion: Do NOT induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or 
water. Never give anything by mouth to an unconscious person. Get medical aid.  
Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give 
artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-
to-mouth resuscitation.  
Notes to Physician: Treat symptomatically and supportively.  
Section 5 - Fire Fighting Measures  
 
 
General Information: Wear appropriate protective clothing to prevent contact with skin and 
eyes. Wear a self-contained breathing apparatus (SCBA) to prevent contact with thermal 
decomposition products.  
Extinguishing Media: Use extinguishing media most appropriate for the surrounding fire.  
Flash Point: Not applicable.  
Autoignition Temperature: Not applicable.  
Explosion Limits, Lower:Not available.  
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Upper: Not available.  
NFPA Rating: (estimated) Health: 2; Flammability: 0; Instability: 0  
Section 6 - Accidental Release Measures  
 
 
General Information: Use proper personal protective equipment as indicated in Section 8.  
Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Clean 
up spills immediately, observing precautions in the Protective Equipment section. Avoid 
generating dusty conditions. Provide ventilation.  
Section 7 - Handling and Storage  
 
 
Handling: Wash thoroughly after handling. Use with adequate ventilation. Minimize dust 
generation and accumulation. Keep container tightly closed. Do not get on skin or in eyes. Do 
not ingest or inhale. Wash clothing before reuse. Always use cool water when dissolving 
Calcium Chloride. Heat evolved is significant.  
Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from 
incompatible substances. Store protected from moisture. Store below melting point.  
Section 8 - Exposure Controls, Personal Protection  
 
 
Engineering Controls: Facilities storing or utilizing this material should be equipped with an 
eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations 
low.  
Exposure Limits  
Chemical Name ACGIH NIOSH OSHA - Final PELs 
Calcium chloride none listed none listed none listed 
 
OSHA Vacated PELs: Calcium chloride: No OSHA Vacated PELs are listed for this chemical.  
Personal Protective Equipment  
Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by 
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OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.  
Skin: Wear impervious gloves.  
Clothing: Wear appropriate protective clothing to minimize contact with skin.  
Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European 
Standard EN 149. Always use a NIOSH or European Standard EN 149 approved respirator when 
necessary.  
Section 9 - Physical and Chemical Properties  
 
 
Physical State: Solid  
Appearance: white  
Odor: odorless  
pH: Not available.  
Vapor Pressure: Not available.  
Vapor Density: Not available.  
Evaporation Rate:Not available.  
Viscosity: Not available.  
Boiling Point: > 1600 deg C @ 760.00mm Hg  
Freezing/Melting Point:782 deg C  
Decomposition Temperature:Not available.  
Solubility: freely soluble in alcohol  
Specific Gravity/Density:2.1500g/cm3  
Molecular Formula:CaCl2  
Molecular Weight:110.99  
Section 10 - Stability and Reactivity  
 
 
Chemical Stability: Stable.  
Conditions to Avoid: Dust generation, excess heat, exposure to moist air or water.  
Incompatibilities with Other Materials: Bromine trifluoride, 2-Furanpercarboxylic Acid, 
Solutions attack some metals..  
Hazardous Decomposition Products: Hydrogen chloride, calcium oxide.  
Hazardous Polymerization: Has not been reported.  
Section 11 - Toxicological Information  
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RTECS#:  
CAS# 10043-52-4: EV9800000  
LD50/LC50: 
CAS# 10043-52-4: 
Oral, mouse: LD50 = 1940 mg/kg; 
Oral, rabbit: LD50 = 1384 mg/kg; 
Oral, rat: LD50 = 1 gm/kg;<br. 
 
Carcinogenicity: 
CAS# 10043-52-4: Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.  
Epidemiology: No information found.  
Teratogenicity: No information found.  
Reproductive Effects: No information found.  
Neurotoxicity: No information found.  
Mutagenicity: Mutagenic effects have occurred in experimental animals.  
Other Studies: See actual entry in RTECS for complete information. </br. 
Section 12 - Ecological Information  
 
No information available.  
Section 13 - Disposal Considerations  
 
Chemical waste generators must determine whether a discarded chemical is classified as a 
hazardous waste. US EPA guidelines for the classification determination are listed in 40 CFR 
Parts 261.3. Additionally, waste generators must consult state and local hazardous waste 
regulations to ensure complete and accurate classification.  
RCRA P-Series: None listed.  
RCRA U-Series: None listed.  
Section 14 - Transport Information  
 
 
US DOT IATA RID/ADR IMO 
Canada 
TDG 
Shipping Name: No 
information    
No 
information 
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available. available. 
Hazard Class: 
     
UN Number: 
     
Packing Group: 
     
 
Section 15 - Regulatory Information  
 
US FEDERAL 
 
TSCA  
CAS# 10043-52-4 is listed on the TSCA inventory.  
Health & Safety Reporting List 
None of the chemicals are on the Health & Safety Reporting List.  
Chemical Test Rules 
None of the chemicals in this product are under a Chemical Test Rule.  
Section 12b 
None of the chemicals are listed under TSCA Section 12b.  
TSCA Significant New Use Rule 
None of the chemicals in this material have a SNUR under TSCA.  
SARA 
 
CERCLA Hazardous Substances and corresponding RQs 
None of the chemicals in this material have an RQ.  
SARA Section 302 Extremely Hazardous Substances 
None of the chemicals in this product have a TPQ.  
SARA Codes 
CAS # 10043-52-4: acute, chronic, reactive.  
Section 313 
No chemicals are reportable under Section 313.  
Clean Air Act: 
This material does not contain any hazardous air pollutants. This material does not contain any 
Class 1 Ozone depletors. This material does not contain any Class 2 Ozone depletors.  
Clean Water Act: 
None of the chemicals in this product are listed as Hazardous Substances under the CWA. None 
of the chemicals in this product are listed as Priority Pollutants under the CWA. None of the 
chemicals in this product are listed as Toxic Pollutants under the CWA.  
OSHA: 
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None of the chemicals in this product are considered highly hazardous by OSHA.  
STATE 
CAS# 10043-52-4 is not present on state lists from CA, PA, MN, MA, FL, or NJ.  
California No Significant Risk Level: None of the chemicals in this product are listed.  
 
European/International Regulations 
European Labeling in Accordance with EC Directives 
Hazard Symbols: 
XI  
Risk Phrases: 
R 36 Irritating to eyes.  
 
Safety Phrases: 
S 22 Do not breathe dust.  
S 24 Avoid contact with skin.  
 
WGK (Water Danger/Protection) 
CAS# 10043-52-4: 0  
Canada - DSL/NDSL 
CAS# 10043-52-4 is listed on Canada's DSL List.  
Canada - WHMIS 
This product has a WHMIS classification of D2B.  
Canadian Ingredient Disclosure List 
Exposure Limits 
Section 16 - Additional Information  
 
MSDS Creation Date: 6/29/1998  
Revision #5 Date: 11/19/2001  
 
The information above is believed to be accurate and represents the best information currently 
available to us. However, we make no warranty of merchantability or any other warranty, 
express or implied, with respect to such information, and we assume no liability resulting from 
its use. Users should make their own investigations to determine the suitability of the information 
for their particular purposes. In no event shall Fisher be liable for any claims, losses, or 
damages of any third party or for lost profits or any special, indirect, incidental, consequential 
or exemplary damages, howsoever arising, even if Fisher has been advised of the possibility of 
such damages.  
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16.1.4 Phosphate Buffered Solution (PBS) 
Material Safety Data Sheet 
PBS Phosphate Buffered Saline 
ACC# 89342  
Section 1 - Chemical Product and Company Identification 
MSDS Name: PBS Phosphate Buffered Saline  
Catalog Numbers: BP661-10, BP661-50, BP665-1  
Synonyms: None.  
Company Identification: 
              Fisher Scientific 
              1 Reagent Lane 
              Fair Lawn, NJ 07410  
For information, call: 201-796-7100  
Emergency Number: 201-796-7100  
For CHEMTREC assistance, call: 800-424-9300  
For International CHEMTREC assistance, call: 703-527-3887  
Section 2 - Composition, Information on Ingredients  
 
CAS# Chemical Name Percent EINECS/ELINCS 
7647-14-5 Sodium Chloride 81.0  231-598-3 
7558-79-4 Sodium phosphate, dibasic ~14  231-448-7 
7778-77-0 Potassium phosphate, Monobasic ~3.0  231-913-4 
7447-40-7 Potassium chloride ~2.0  231-211-8 
 
Section 3 - Hazards Identification  
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EMERGENCY OVERVIEW 
Appearance: white solid. 
Warning! Causes eye irritation. May cause skin and respiratory tract irritation.  
Target Organs: Eyes.  
 
 
Potential Health Effects  
Eye: Causes eye irritation.  
Skin: May cause skin irritation.  
Ingestion: Ingestion of large amounts may cause gastrointestinal irritation. May cause gastric 
disturbances and electrolytic imbalance. Ingestion of large amounts of sodium chloride may 
cause nausea, and vomiting, rigidity or convulsions. Continued exposure can produce coma, 
dehydration and internal organ congestion.  
Inhalation: Inhalation of dust may cause respiratory tract irritation.  
Chronic: No information found.  
Section 4 - First Aid Measures  
 
 
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and 
lower eyelids. Get medical aid.  
Skin: Flush skin with plenty of water for at least 15 minutes while removing contaminated 
clothing and shoes. Get medical aid if irritation develops or persists. Wash clothing before reuse.  
Ingestion: Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or 
water. Never give anything by mouth to an unconscious person. Get medical aid.  
Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give 
artificial respiration. If breathing is difficult, give oxygen. Get medical aid.  
Notes to Physician: Treat symptomatically and supportively.  
Section 5 - Fire Fighting Measures  
 
 
General Information: As in any fire, wear a self-contained breathing apparatus in pressure-
demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, 
irritating and highly toxic gases may be generated by thermal decomposition or combustion. 
Substance is noncombustible.  
Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam.  
Flash Point: Not applicable.  
Autoignition Temperature: Not applicable.  
Explosion Limits, Lower:Not available.  
Diamond HemeSep Blood Processing Unit  Moonan, Paranjape, Tirone, Wang 
 
132 
Upper: Not available.  
NFPA Rating: (estimated) Health: 2; Flammability: 0; Instability: 0  
Section 6 - Accidental Release Measures  
 
 
General Information: Use proper personal protective equipment as indicated in Section 8.  
Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Clean 
up spills immediately, observing precautions in the Protective Equipment section. Avoid 
generating dusty conditions. Provide ventilation.  
Section 7 - Handling and Storage  
 
 
Handling: Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with 
eyes, skin, and clothing. Avoid ingestion and inhalation.  
Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from 
incompatible substances.  
Section 8 - Exposure Controls, Personal Protection  
 
 
Engineering Controls: Facilities storing or utilizing this material should be equipped with an 
eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations 
low.  
Exposure Limits  
Chemical Name ACGIH NIOSH OSHA - Final PELs 
Sodium Chloride  none listed  none listed  none listed  
Sodium phosphate, 
dibasic  
none listed  none listed  none listed  
Potassium phosphate, 
Monobasic  
none listed  none listed  none listed  
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Potassium chloride  none listed  none listed  none listed  
 
OSHA Vacated PELs: Sodium Chloride: No OSHA Vacated PELs are listed for this chemical. 
Sodium phosphate, dibasic: No OSHA Vacated PELs are listed for this chemical. Potassium 
phosphate, Monobasic: No OSHA Vacated PELs are listed for this chemical. Potassium chloride: 
No OSHA Vacated PELs are listed for this chemical.  
Personal Protective Equipment  
Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by 
OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.  
Skin: Wear appropriate protective gloves to prevent skin exposure.  
Clothing: Wear appropriate protective clothing to prevent skin exposure.  
Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European 
Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if 
exposure limits are exceeded or if irritation or other symptoms are experienced.  
Section 9 - Physical and Chemical Properties  
 
 
Physical State: Solid  
Appearance: white  
Odor: none reported  
pH: Not available.  
Vapor Pressure: Not available.  
Vapor Density: Not available.  
Evaporation Rate:Not available.  
Viscosity: Not available.  
Boiling Point: Not available.  
Freezing/Melting Point:Not available.  
Decomposition Temperature:Not available.  
Solubility: Soluble.  
Specific Gravity/Density:Not available.  
Molecular Formula:Mixture  
Molecular Weight:Not available.  
Section 10 - Stability and Reactivity  
 
 
Chemical Stability: Stable.  
Conditions to Avoid: Dust generation, excess heat.  
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Incompatibilities with Other Materials: Potassium chloride is incompatible with potassium 
permanganate. Sodium chloride is incompatible with dichloromaleic anhydride + urea, lithium, 
and nitrogen compounds. Potassium phosphate dibasic and monobasic may react violently with 
strong acids.  
Hazardous Decomposition Products: Oxides of phosphorus, sodium oxide, oxides of 
potassium.  
Hazardous Polymerization: Will not occur.  
Section 11 - Toxicological Information  
 
 
RTECS#:       
CAS# 7647-14-5: VZ4725000       
CAS# 7558-79-4: WC4500000       
CAS# 7778-77-0: TC6615500       
CAS# 7447-40-7: TS8050000  
LD50/LC50: 
CAS# 7647-14-5: 
     Draize test, rabbit, eye: 100 mg Mild; 
     Draize test, rabbit, eye: 100 mg/24H Moderate; 
     Draize test, rabbit, eye: 10 mg Moderate; 
     Draize test, rabbit, skin: 50 mg/24H Mild; 
     Draize test, rabbit, skin: 500 mg/24H Mild; 
     Inhalation, rat: LC50 = >42 gm/m3/1H; 
     Oral, mouse: LD50 = 4 gm/kg; 
     Oral, rat: LD50 = 3000 mg/kg; 
     Skin, rabbit: LD50 = >10 gm/kg; 
. 
 
CAS# 7558-79-4: 
     Draize test, rabbit, eye: 500 mg/24H Mild; 
     Draize test, rabbit, skin: 500 mg/24H Mild; 
     Oral, rat: LD50 = 17 gm/kg; 
. 
 
CAS# 7778-77-0: 
     Skin, rabbit: LD50 = >4640 mg/kg; 
. 
 
CAS# 7447-40-7: 
     Draize test, rabbit, eye: 500 mg/24H Mild; 
     Oral, mouse: LD50 = 1500 mg/kg; 
     Oral, rat: LD50 = 2600 mg/kg; 
. 
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Carcinogenicity: 
CAS# 7647-14-5: Not listed by ACGIH, IARC, NTP, or CA Prop 65. 
CAS# 7558-79-4: Not listed by ACGIH, IARC, NTP, or CA Prop 65. 
CAS# 7778-77-0: Not listed by ACGIH, IARC, NTP, or CA Prop 65. 
CAS# 7447-40-7: Not listed by ACGIH, IARC, NTP, or CA Prop 65. 
 
Epidemiology: No information found  
Teratogenicity: No information found  
Reproductive Effects: No information found  
Mutagenicity: No information found  
Neurotoxicity: No information found  
Other Studies:  
Section 12 - Ecological Information  
 
No information available.  
Section 13 - Disposal Considerations  
 
Chemical waste generators must determine whether a discarded chemical is classified as a 
hazardous waste. US EPA guidelines for the classification determination are listed in 40 CFR 
Parts 261.3. Additionally, waste generators must consult state and local hazardous waste 
regulations to ensure complete and accurate classification.  
RCRA P-Series: None listed.  
RCRA U-Series: None listed.  
Section 14 - Transport Information  
 
 
US DOT Canada TDG 
Shipping Name: Not regulated as a hazardous material No information available. 
Hazard Class: 
  
UN Number: 
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Packing Group: 
  
 
Section 15 - Regulatory Information  
 
US FEDERAL 
 
TSCA  
     CAS# 7647-14-5 is listed on the TSCA inventory.  
     CAS# 7558-79-4 is listed on the TSCA inventory.  
     CAS# 7778-77-0 is listed on the TSCA inventory.  
     CAS# 7447-40-7 is listed on the TSCA inventory.  
Health & Safety Reporting List 
     None of the chemicals are on the Health & Safety Reporting List.  
Chemical Test Rules 
     None of the chemicals in this product are under a Chemical Test Rule.  
Section 12b 
     None of the chemicals are listed under TSCA Section 12b.  
TSCA Significant New Use Rule 
     None of the chemicals in this material have a SNUR under TSCA.  
CERCLA Hazardous Substances and corresponding RQs 
     CAS# 7558-79-4: 5000 lb final RQ; 2270 kg final RQ  
SARA Section 302 Extremely Hazardous Substances 
     None of the chemicals in this product have a TPQ.  
SARA Codes 
     CAS # 7647-14-5: immediate.  
     CAS # 7778-77-0: immediate.  
     CAS # 7447-40-7: immediate.  
Section 313  
     This material contains Potassium chloride (listed as Water Dissociable Nitrate Compounds), 
~2.0%, (CAS# 7447-40-7) which is subject to the reporting requirements of Section 313 of 
SARA Title III and 40 CFR Part 373.  
Clean Air Act: 
     This material does not contain any hazardous air pollutants.  
     This material does not contain any Class 1 Ozone depletors.  
     This material does not contain any Class 2 Ozone depletors.  
Clean Water Act: 
CAS# 7558-79-4 is listed as a Hazardous Substance under the CWA.  
     None of the chemicals in this product are listed as Priority Pollutants under the CWA.  
     None of the chemicals in this product are listed as Toxic Pollutants under the CWA.  
OSHA: 
     None of the chemicals in this product are considered highly hazardous by OSHA.  
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STATE 
     CAS# 7647-14-5 is not present on state lists from CA, PA, MN, MA, FL, or NJ.  
     CAS# 7558-79-4 can be found on the following state right to know lists: California, New 
Jersey, Pennsylvania, Massachusetts.  
     CAS# 7778-77-0 is not present on state lists from CA, PA, MN, MA, FL, or NJ.  
     CAS# 7447-40-7 is not present on state lists from CA, PA, MN, MA, FL, or NJ.  
 
California Prop 65 
 
California No Significant Risk Level: None of the chemicals in this product are listed.  
 
European/International Regulations 
European Labeling in Accordance with EC Directives 
Hazard Symbols: 
      Not available.  
Risk Phrases: 
 
Safety Phrases: 
 
WGK (Water Danger/Protection) 
     CAS# 7647-14-5: 0  
     CAS# 7558-79-4: 1  
     CAS# 7778-77-0: 1  
     CAS# 7447-40-7: 1  
Canada - DSL/NDSL 
     CAS# 7647-14-5 is listed on Canada's DSL List.  
     CAS# 7558-79-4 is listed on Canada's DSL List.  
     CAS# 7778-77-0 is listed on Canada's DSL List.  
     CAS# 7447-40-7 is listed on Canada's DSL List.  
Canada - WHMIS 
     This product has a WHMIS classification of D2B.  
This product has been classified in accordance with the hazard criteria of the Controlled Products 
Regulations and the MSDS contains all of the information required by those regulations.  
Canadian Ingredient Disclosure List 
     CAS# 7447-40-7 is not listed on the Canadian Ingredient Disclosure List. 
Section 16 - Additional Information  
 
MSDS Creation Date: 7/16/1999  
Revision #6 Date: 6/29/2007  
 
The information above is believed to be accurate and represents the best information currently 
available to us. However, we make no warranty of merchantability or any other warranty, 
express or implied, with respect to such information, and we assume no liability resulting from 
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its use. Users should make their own investigations to determine the suitability of the information 
for their particular purposes. In no event shall Fisher be liable for any claims, losses, or 
damages of any third party or for lost profits or any special, indirect, incidental, consequential 
or exemplary damages, howsoever arising, even if Fisher has been advised of the possibility of 
such damages.  
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16.1.5 Tris-Buffered Solution (TBS) 
 
Close This Browser Window to Return to Data Sheet Index  
 
MATERIAL SAFETY DATA SHEET  
Effective Date: July 23, 2010  
 
SECTION 1 PRODUCT AND COMPANY IDENTIFICATION 
 
PRODUCT 
NAME: 
para-tertiary-
Butylstyrene 
CHEMICAL 
SYNONYMS: 
1-(1,1-Dimethylethyl)-4-
ethenylbenzene 
PRODUCT 
CODE: 
TBS 
CHEMICAL 
FAMILY: 
Aromatic Hydrocarbon 
PRODUCT USE: Specialty Monomer   
  
COMPANY 
NAME: 
Deltech Corporation   
  
11911 Scenic 
Highway 
  
  
Baton Rouge, LA 
70807 
  
  
24 Hour EMERGENCY 
PHONE 
(01) 225 772-0150 CHEMTREC: 
1-800 424-
9300 
  
 
SECTION 2 
COMPOSITION/INFORMATION ON 
INGREDIENTS 
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Component (CAS #) % By Weight Exposure Limits 
  
p-tert-Butylstyrene (1746-23-2)   94-96 Not Established 
tert-Butylethylbenzene (37871-
12-8) 
    2- 3 Not Established 
m-tert-Butylstyrene (19789-36-
7) 
    1- 3 Not Established 
  
This material is Hazardous by definition of Hazard Communication Standard (29 CFR 
1910.1200).  
  
 
SECTION 3 HAZARD IDENTIFICATION 
 
EMERGENCY OVERVIEW 
TBS is water-white liquid with aromatic odor. TBS is a moderate eye, respiratory 
system and skin irritant. TBS may polymerize and autoaccelerate if exposed to heat or 
mixed with catalyst, peroxide, metal halide, acids, or oxidizing agents resulting in 
rapid temperature rise and increased volatilization. Combustible. Hot vapors are 
extremely flammable and are heavier than air.  
POTENTIAL HEALTH EFFECTS:  
EYE: Vapors may cause irritation. Liquid is strong eye irritant.  
SKIN: Exposure may cause redness and irritation of the skin. May cause drying and flaking 
of the skin. A single, prolonged exposure is not likely to result in the material being 
absorbed through the skin in harmful amounts.  
INGESTION: Substance may be harmful if swallowed, although it is unlikely to have 
serious health effects in minute quantities. May cause central nervous system depression 
(dizziness, drowsiness), nausea and loss of consciousness.  
INHALATION: Avoid breathing vapors or mists, may be harmful if inhaled. Because of 
low vapor pressure it is unlikely that TBS will be inhaled in harmful amounts. If heated or 
misted, concentrations may be attained that may be hazardous from a single exposure. 
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Irritation to the upper respiratory tract and lungs, central nervous system depression 
(dizziness, drowsiness), nausea and loss of consciousness are common consequences of 
inhalation overexposure  
CHRONIC (CANCER) INFORMATION: No Data.  
TERATOLOGY (BIRTH DEFECT) INFORMATION: No Data.  
REPRODUCTION INFORMATION: No Data.  
POTENTIAL ENVIRONMENTAL EFFECTS: No Data. The low volatility should 
significantly limit persistence and mitigate the potential to produce adverse environmental 
impacts.  
  
 
SECTION 4 FIRST AID MEASURES 
 
EYES: Flush eyes thoroughly with water for 15 minutes. Consult physician if irritation 
persists.  
SKIN: Wash affected area with soap and water. Remove contaminated clothing and shoes. 
Do not reuse contaminated clothing without laundering. Consult physician if irritation 
persists.  
INGESTION: Do not induce vomiting; consult physician immediately.  
INHALATION: Remove victim to fresh air. Get medical assistance immediately. May 
cause chemical pneumonia if aspirated. Administer oxygen if there is difficulty breathing. 
Administer artificial respiration if not breathing.  
NOTE TO PHYSICIANS 
Because rapid absorption may occur through the lungs if aspirated, the decision of whether 
to induce vomiting should be made by a physician. If lavage is performed, suggest 
endotracheal and/or esophageal control. Danger from lung aspiration must be weighed 
against toxicity when considering emptying the stomach. Treat burns as thermal burns. 
Treatment based upon judgement of the physician in response to the reactions of the patient.  
  
 
SECTION 5 FIRE FIGHTING MEASURES 
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FLAMMABLE 
PROPERTIES: 
Flash Point: 177 
°F    Method: TCC 
  
 
Flammable. Hot vapors are heavier than air and very flammable. Vapors may travel 
considerable distances to ignition source and cause flash fires or explosions. 
FLAMMABILITY 
LIMITS:  (212 °F) 
Lower Flammablity Limit: 1.0% 
  Upper Flammablity Limit: 2.7% 
AUTOIGNITION 
TEMPERATURE: 
813°F (434°C) 
 
HAZARDOUS COMBUSTION PRODUCTS: Carbon dioxide, carbon monoxide, and 
other toxic fumes of incomplete combustion. During a fire, smoke may contain mists of the 
original material.  
EXTINGUISHING MEDIA: Carbon dioxide, foam or dry chemical. Water fog or fine 
spray; water may be ineffective. General purpose synthetic foams or protein foams are 
preferred.  
FIRE FIGHTING INSTRUCTIONS: Use water spray to cool fire exposed containers, 
protect personnel, and disperse vapors and spills. Dike and collect water due to potential 
environmental damage and spread of fire with product carried across water surface. Use 
self-contained breathing apparatus and fight fire from safe distance due to explosion 
potential.  
UNUSUAL HAZARDS ASSOCIATED WITH FIRE: Closed containers of TBS may 
build up explosive pressures when exposed to the heat of fires. Closed containers of TBS 
exposed to the heat of fires may begin to polymerize in an exothermic manner leading to 
autoacceleration and rapid pressure increase and explosion potential.  
  
 
SECTION 6 ACCIDENTAL RELEASE MEASURES 
 
SMALL SPILL: Absorb spill with an inert material (dry sand) and place in chemical waste 
container for disposal (see section 13). Do not use reactive absorbents.  
LARGE SPILL(on land): Remove all sparking devices and ignition sources. Contain 
spilled liquid with dikes of earth. Pump water into diked area and collect product from the 
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top of water. Dispose of hydrocarbon laden water accordingly. Use oil spill collection pads 
and booms to contain runoff and seepage from diked areas.  
SPILLS INTO WATERWAYS: Contain spill with oil booms and recover product by 
vacuum truck or oil collection pads.  
REPORTABLE QUANTITY: Not a DOT listed Hazardous Substance. Various state and 
local regulations may apply.  
  
 
SECTION 7 HANDLING AND STORAGE 
 
HANDLING: Avoid contact with eyes. Avoid prolonged or repeated contact with skin. 
Keep containers tightly closed and use in well ventilated areas. Avoid prolonged or repeated 
breathing of vapors. Use grounding and bonding connections when transferring material to 
prevent static discharge, fire or explosion. Use spark proof tools and explosion proof 
equipment. Even empty containers may contain vapors. Do not cut, drill, grind or weld on 
containers, even if emptied of product.  
STORAGE: Store in a cool area or refrigerated tank away from high temperatures, hot 
pipes or direct sunlight. Maintain TBS temperature in storage below 90°F (32°C). Maintain 
inhibitor concentration above 50 ppm. If storage of more than 6 weeks is required aerate 
once per week with dry air to maintain dissolved oxygen above 10 ppm.  
  
 
SECTION 8 
EXPOSURE CONTROLS / PERSONAL 
PROTECTION  
 
ENGINEERING CONTROLS: Use local ventilation to maintain airborne concentrations 
below exposure limits. Use only with adequate ventilation.  
RESPIRATORY PROTECTION: For operations where inhalation exposure may occur, a 
NIOSH approved air purifying respirator with organic vapor cartridge(s) or canister may be 
permissible. Protection provided by air purifying respirators is limited. Use a positive-
pressure air-supplied respirator if there is any potential for uncontrolled release or any other 
circumstances where air-purifying respirators may not provide adequate protection.  
SKIN PROTECTION: When contact may occur, use protective clothing and gloves 
impervious to hydrocarbon materials. Use of specific items such as face shield, apron, 
gloves, boots or body suit is dependent upon operation. Wash hands thoroughly before 
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eating, drinking or smoking.  
EYE PROTECTION: Use safety glasses when handling small amounts. When splashing 
may occur use chemical splash goggles and face shield. If vapors cause eye discomfort use a 
full-face, supplied-air respirator.  
  
 
SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES  
 
BOILING POINT 426°F (219°C) 
MELTING POINT: -36°F (-38°C) 
VAPOR PRESSURE: 0.18 mmHG @68°F (20°C) 
VAPOR DENSITY: 5.55 (air=1) 
SOLUBILITY IN WATER: Insoluble (5 ppm) 
DENSITY: 0.884 g/cc @ 77°F (25°C) 
pH: N/A 
ODOR: Strong Aromatic Hydrocarbon 
APPEARANCE: Colorless Liquid 
  
 
SECTION 10 STABILITY AND REACTIVITY 
 
CHEMICAL STABILITY: Stable under recommended storage conditions. Inhibited with 
tertiary-butyl-catechol (TBC). Maintain temperature below 90°F (32°C). Maintain oxygen 
content above 10 ppm.  
CONDITIONS TO AVOID: Do not blanket with inert gas to avoid depleting dissolved 
oxygen concentration. Avoid excessive heat and keep away from open flames or ignition 
sources. Avoid dead-headed pumps while transferring.  
INCOMPATABILITY: Do not use copper or brass tubing or connections. Do not mix 
with oxidizing agents, acids, metal halides or peroxides.  
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HAZARDOUS DECOMPOSITON PRODUCTS : None known.  
HAZARDOUS POLYMERIZATION: Polymerization may occur if exposed to excessive 
heat or catalyzed by mixture with incompatible materials. Polymerization is exothermic and 
may result in autoacceleration and increased pressure, venting of container, and a fire or 
explosion hazard.  
  
 
SECTION 11 TOXICOLOGICAL INFORMATION 
 
EYE EFFECTS: No Data. Would be expected to be a mild to moderate eye irritant with 
toxicity resembling that of styrene.  
SKIN EFFECTS: No Data. Would be expected to be a mild to moderate skin irritant with 
toxicity resembling that of styrene.  
ACUTE ORAL EFFECTS: Oral LD50 in rats is >2000mg/kg.  
ACUTE INHALATION EFFECTS: No Data. Would be expected to be a mild to 
moderate respiratory irritant with toxicity resembling that of styrene.  
SUBCHRONIC EFFECTS: No Data.  
CHRONIC EFFECTS / CARCINOGENICITY: No Data.  
TERATOLOGY: No Data.  
REPRODUCTION: No Data.  
MUTAGENICITY: No Data.  
  
 
SECTION 12 ECOLOGICAL INFORMATION 
 
ECOTOXICITY: The 96 hour static LC50 for fathead minnows is ~2 mg/L. The 48 hour 
static LC50 for Daphnia magna is ~1 mg/L. In each case the “No observed adverse effect” 
level was approximately 50% of LC50.  
CHEMICAL FATE INFORMATION: Biodegradation under aerobic conditions is 
expected to be low, however the material is expected to biodegrade in a wastewater 
treatment plant. TBS is not expected to bioconcentrate in aquatic systems.  
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SECTION 13 DISPOSAL CONSIDERATIONS 
 
DISPOSAL: Do not dump into sewers, on the ground, into any body of water or into 
municipal or industrial waste receptacles. Disposal must be in accordance with all local, 
state and Federal/Provincial laws and regulations governing the disposal of chemical wastes. 
The preferred method of disposal for unusable or contaminated product is sending to a 
licensed, permitted incinerator or thermal destruction device. The heat of combustion of the 
material in the product form is approximately 18,000 BTUs/lb.  
RECYCLING OPPORTUNITIES: Downgraded or unused product could possibly be 
returned to Deltech for recycling if certain criteria are met. Contact a Deltech sales 
representative for more information.  
  
 
SECTION 14 TRANSPORT INFORMATION 
 
PROPER SHIPPING NAME Combustible Liquid, N.O.S. 
  (Para-Tertiary-Butyl Styrene, Stabilized) 
  NA 1993, PGIII 
  
OTHER DOT 
REQUIREMENTS 
Not regulated in drum quantities (non-bulk) 
  
 
SECTION 15 REGULATORY INFORMATION 
 
Not meant to be all inclusive. 
US FEDERAL / STATE REGULATIONS:  
CERCLA: SARA TITLE III SECTIONS 311 AND 312 HAZARD CATEGORY: 
  Acute Health Hazard 
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  Fire Hazard 
  Chronic Health Hazard 
  This notice must not be detached from the MSDS.  
TSCA: Listed  
PENNSYLVANIA RIGHT-TO-KNOW HAZARDOUS SUBSTANCES (34 Pa. Code 
Chap. 301-323) (Threshold 1%): Listed  
INTERNATIONAL REGULATIONS:  
CANADIAN DSL INVENTORY: Listed  
EINCS: This product is on the European Inventory of Existing Commercial Chemical 
Substances. EINECS Inventory Number: 2171269  
  
 
SECTION 16 OTHER INFORMATION 
 
MSDS STATUS:  
All sections revised to bring MSDS in compliance with the ANSI Z400.1-1998 Standard 
(10/02).  
NATIONAL FIRE PROTECTION ASSOCIATION (NFPA) SYSTEM RATING:  
The NFPA system rating for this product is:  Fire - 2    Health - 2    Reactivity - 2  
This material may be regulated by Louisiana's Right-To-Know Law, R.S.30:2361 ET SEQ.  
 
Deltech believes the information and recommendations contained herein to be accurate and 
reliable. Since the foregoing is provided without charge and since use conditions and disposal are 
not within its control, Deltech assumes no obligation or liability for such information and 
recommendations and does not guarantee results from use of products described or other 
information contained herein. Deltech makes no warranties, express or implied, including 
merchantability or fitness for purpose; nor is freedom from any patent owned by Deltech or 
others to be inferred; and Deltech disclaims all liability for any resulting loss or damage.  
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16.1.6 Cell Lysis Buffer 
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16.1.7 Dynabeads 
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16.1.8 AntiCD45RA Antibody 
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16.2 Reagent Volume 
16.2.1 Serum Filtration Calculations 
5x10^(-4) mg of thrombin with an activity of 400 NIH units/mg is hydrated with 10 
microL of TBS buffer to arrive at a concentration of .05mg thrombin/mL .  This is added to 200 
microL of plasma to arrive at a concentration of 1NIH unit/mL. 
 
Assuming we need to neutralize it all citrate, it will take 34mg CaCl2.  If this is hydrated 
with 10microL TBS, you arrive at a concentration of 3.5M, which may not be possible.  We can 
likely use less, probably ~5-15mg of CaCl2. 
Immunomagnetic Precipitation Calculations: 
Per the manufacturer’s protocol (attached next), 25 µL of antibody is needed for 2 mL of 
whole blood used.  However, the protocol has been modified to run under a shorter amount of 
time.  Based on the antibody binding chart displayed in Chapter 7, we assumed a minimum of 
50% antibody binding in 5 minutes.  Therefore, for 1 mL of whole blood processed we assumed 
25 µL of antibody would be necessary.  Conservatively accounting for losses in the wash steps, 
this number was doubled to 50 µL. Likewise, the manufacturer’s protocol calls for 75 µL of 
beads per 2 mL of whole blood.  Under the same assumptions, this number was doubled and then 
a small portion added to give 100 µL for 1 mL of whole blood under the time-modified 
procedure used in our cartridge. 
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16.3 Channel Bifurcation Calculations 
COMSOL was used to calculate the fluid mechanics involved with blood flowing through 
the microfluidic channels.  This was done according to the procedure outlined in Equations 4.1 
through 4.3.  Specifically, the average velocities were calculated by creating cut lines as shown 
below: 
 
COMSOL then reported an average velocity across the cutline.  These values were used as 
outlined in Chapter 4 to calculate the flow rate ratios as in the example trials. 
 Since we were told to have a plasma output of > 100 µL and a serum output of  > 100 µL, 
this necessitated that the microfluidic device be capable of outputting at least 200 µL of 
relatively pure plasma in the allotted run time.  Assuming a flowrate of 10.5 µL/min and, for the 
design parameters of a main channel width of 60 µm and daughter channel width of 15 µm, the 
following calculations were used to determine total plasma output for a run time of 20 minutes: 
                                  
      (1) 
Then, the flowrates through each of the daughter channels was calculated as: 
                               (2) 
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The flow rates through each of the daughter channels were then added as follows: 
          ∑                                   ∑            
        (3) 
The total plasma volume is then given by: 
                                            
   (
  
 
)                 (4) 
Since this volume came from a flow rate of 10.5 µL/min, for 20 minutes, 840 µL of whole blood 
was required, indicating that for the first bifurcation process, half this amount is needed (420 µL 
indicating at least 105 µL are needed in each well).  Conservatively, we placed 120 µL of whole 
blood in each well for each bifurcation step.  The amount of plasma being taken from the whole 
blood is therefore 27.8% by volume, which seems reasonable given that blood is nearly 55% 
plasma by volume. 
These calculations seemed adequate for the given design but can be modified during the 
trial year as necessary and according to experimental data. 
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16.4 Darcy’s Law Calculation 
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Flow rate through membrane =       
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16.5 Financial Appendix 
16.5.1 Market Projections 
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16.5.2 Inventory Costs 
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16.5.3 Operating Assumptions 
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16.5.4 Inventory, Working Capital, PP&E 
 
Diamond HemeSep Blood Processing Unit  Moonan, Paranjape, Tirone, Wang 
 
169 
16.5.5 Income Statement 
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16.5.6 Free Cash Flow 
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16.5.7 Valuation and Returns 
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16.5.8 Payback Period 
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